  
Confidential Information  
Information in this protocol is confidential and should not be disclosed, other than to those directly involved in the 
execution or the ethical review of the study, without written authorization from Medicago R&D Inc. (h erein after 
known as “Medicago”), an d its affiliates. This study will be conducted in accordance with applicable Good Clinical 
Practice (GCP) guidelines, the United States Code of Federal Regulations (CFR), and International Conference on 
Harmonization (ICH) guidelines . 
 
Clinical Protocol 
A Randomized, Observer-blind, Active Comparator- controlled, Multicenter, Phase 3 
Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-d erived 
Quadrivalent VLP Influenza Vaccine in Adults 65 Years of Age and Older  
 
CP-PRO -QVLP -014; Phase 3 
 
Plant -derived Quadrivalent VLP Influenza Vaccine 
 
Name of Sponsor: Medicago R&D Inc. 
1020 route de l’Église, bureau 600 
Québec (Q C), Canada G1V 3V9  
  
  
  
  
Status: Final version 1 .2 
  
Date: July 24th, 2018 
 
  
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 3 of 90 COORDINATING INVESTIGATOR SIGNATURE  
Study Title: A Randomized, Observer-blind, Active Comparator-controlled, 
Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-derived Quadrivalent VLP Influenza Vaccine in Adults 65 Years of Age and Older 
 
I have read the version 1.2 (dated  July 24th, 2018) Protocol No. CP -PRO-QVLP-014 titled, “ A 
Randomized, Observer-blind, Active Comparator-controlled, Multicenter, Phase 3 Study to 
Assess the Efficacy, Safety, and Immunogenicity of a Plant-derived Quadrivalent VLP Influenza Vaccine in Adults 65 Years of Age and Older ”. 
I have fully discussed the objectives of this study and the contents of this protocol with the Sponsor’s representative and I agree to accept the responsibility to act as Coordinating Investigator for this study. 
 
Coordinating Investigator: 
 
 
Signature  
  
  Date (YYYY -MM-DD) 
 
  
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 4 of 90 INVESTIGATOR AGREEMENT  
I have read the version 1.2 (dated July 24th, 2018) Protocol No. CP -PRO-QVLP-014 titled, “A 
Randomized, Observer-blind, Active Comparator-controlled, Multicenter, Phase 3 Study to 
Assess the Efficacy, Safety, and Immunogenicity of a Plant-derived Quadrivalent VLP Influenza Vaccine in Adults 65 Years of Age and Older ”. 
I have fully discussed the objectives of this study and the contents of this protocol with the Sponsor’s representative. 
I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution or the ethical review of the study, without 
prior written authorization from Medicago. It is, however, permissible to discuss information 
contained in this protocol with a subject in order to obtain consent once ins titutional review 
board (IRB) approval is obtained. 
I agree to conduct this study according to this protocol and to comply with its requirements, 
subject to ethical and safety considerations and guidelines, and to conduct the study in accordance with International Conference on Harmonisation (ICH) guidelines, Good Clinical 
Practice (GCP), Investigational New Drug (IND) regulations, and other applicable regulatory requirements.  
I understand that the Sponsor may decide to suspend or prematurely terminate this study at any time for whatever reason and that such a decision will be communicated to me in writing. Conversely, should I decide to withdraw from execution of the study, I will communicate my 
intention immediately in writing to the Sponsor.  
Principa l Investigator: 
Name (typed or 
printed):  
Institution and Address:  
  
  
Telephone Number:  
 
Signature   Date (YYYY-MM-DD) 
 
Note: If the address or the telephone number of the Investigat or changes during the course of 
the study, written notification will be provided by the Investigator to the Sponsor, and a 
protocol amendment will not be required.  
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
Confidentia l Information  
Medicago R&D Inc. Page 5 of 90 TABLE OF CONTENTS  
SIGNATURES  ................................................................................................................................ 2  
COORDINATING INVESTIGATOR SIGNATURE  .................................................................... 3  
INVESTIGATOR AGREEMENT .................................................................................................. 4  
TABLE OF CONTENTS  ................................................................................................................ 5  
LIST OF TABLES  .......................................................................................................................... 9  
SYNOPSIS  .................................................................................................................................... 10  
ABBREVIATIONS  ...................................................................................................................... 24  
1 INTRODUCTION  ................................................................................................................. 26  
1.1 Quadrivalent VLP Influenza Vaccine  ............................................................................ 27  
1.2 Pre-clinical Studies  ......................................................................................................... 27  
1.3 Clinical Studies  .............................................................................................................. 28  
1.3.1  Clinical Safety Overview  ........................................................................................ 29  
1.3.2  Immunogenicity Overview  ..................................................................................... 30  
1.4 Overall Rationale for the Study  ...................................................................................... 31  
2 OBJECTIVES  ........................................................................................................................ 32  
2.1 Primary Objectives  ......................................................................................................... 32  
2.2 Secondary Objectives  ..................................................................................................... 32  
2.3 Exploratory Objectives ................................................................................................... 33  
3 STUDY ADMINISTRATIVE STRUCTURE  ...................................................................... 34  
4 STUDY DESIGN AND RATIONALE  ................................................................................. 34  
4.1 Overview of Study Design ............................................................................................. 34  
4.2 Rationale of Study Design.............................................................................................. 37  
4.2.1  Randomization ........................................................................................................ 37  
4.2.2  Observer-blinding ................................................................................................... 37  
4.2.3  Age Group Stratification  ......................................................................................... 37  
4.2.4  Dose Selection  ........................................................................................................ 37  
4.2.5  Active Comparator Selection  .................................................................................. 37  
4.2.6  Study Duration  ........................................................................................................ 37  
4.2.7  Efficacy Assessments .............................................................................................. 37  
5 STUDY POPULATION  ........................................................................................................ 38  
5.1 Inclusion Criteria  ............................................................................................................ 38  
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 6 of 90 5.2 Exclusion Criteria  ........................................................................................................... 38  
5.3 Prior and Concomitant Therapy ..................................................................................... 40  
5.4 Prohibited Therapy ......................................................................................................... 41  
6 TREATMENT ALLOCATION AND BLINDING .............................................................. 41  
6.1 Randomization ............................................................................................................... 41  
6.2 Blinding .......................................................................................................................... 42  
7 DOSAGE AND ADMINISTRATION  .................................................................................. 42  
8 SPECIMENS AND CLINICAL SUPPLIES  ......................................................................... 43  
8.1 Management of Samples  ................................................................................................ 43  
8.2 Clinical Supplies  ............................................................................................................ 43  
9 TREATMENT COMPLIANCE  ............................................................................................ 43  
10 STUDY EVALUATIONS  ..................................................................................................... 43  
10.1  Study Procedures  ............................................................................................................ 43  
10.1.1  Overview  ................................................................................................................. 43  
10.1.2  Screening/Vaccination (Visit 1)  .............................................................................. 44  
10.1.3  Day 1 and Day 8 (Telephone Contact) ................................................................... 47  
10.1.4  Surveillance for Respiratory Illness  ........................................................................ 48  
10.1.5  Day 21 ..................................................................................................................... 50  
10.1.6  End of Surveillance (Telephone Contact)  ............................................................... 51  
10.2  Efficacy .......................................................................................................................... 51  
10.2.1  Efficacy Evaluations ............................................................................................... 51  
10.2.2  Efficacy Endpoints .................................................................................................. 53  
10.3  Safety .............................................................................................................................. 54  
10.3.1  Evaluations .............................................................................................................. 54  
10.3.2  Safety Endpoints  ..................................................................................................... 56  
10.4  Immunogenicity  ............................................................................................................. 57  
10.4.1  Immunogenicity Evaluations  .................................................................................. 57  
10.4.2  Immunogenicity Endpoints ..................................................................................... 57  
11 SUBJECT COMPLETION/WITHDRAWAL  ...................................................................... 58  
11.1  Temporary Contraindications ......................................................................................... 58  
11.2  Screening Failures  .......................................................................................................... 58  
11.3  Removal of Subjects from Treatment or Assessment  .................................................... 59  
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 7 of 90 11.3.1  Follow-up of Discontinuations ............................................................................... 59  
11.3.2  Lost to Follow-up Procedures ................................................................................. 59  
11.4  Interruption of the Study ................................................................................................ 59  
12 STATISTICAL METHODS .................................................................................................. 60  
12.1  Analysis Populations ...................................................................................................... 60  
12.1.1  Safety Analysis Set  ................................................................................................. 60  
12.1.2  Full Analysis Set ..................................................................................................... 60  
12.1.3  Per Protocol Set ....................................................................................................... 60  
12.2  Sample Size Determination  ............................................................................................ 61  
12.3  Efficacy Analyses  ........................................................................................................... 61  
12.3.1  Analysis of Primary Endpoint ................................................................................. 61  
12.3.2  Analysis of Secondary Endpoints ........................................................................... 62  
12.3.3  Analysis of Exploratory Endpoints ......................................................................... 62  
12.4  Baseline and Subject Disposition ................................................................................... 63  
12.5  Safety Analyses  .............................................................................................................. 63  
12.5.1  Analysis of Secondary Endpoints ........................................................................... 63  
12.5.2  Analysis of Exploratory Endpoint .......................................................................... 63  
12.6  Immunogenicity Analyses  .............................................................................................. 64  
12.6.1  Analysis of Secondary Endpoints ........................................................................... 64  
12.6.2  Analysis of Exploratory Endpoint .......................................................................... 64  
13 ADVERSE EVENT REPORTING  ....................................................................................... 64  
13.1  Definitions  ...................................................................................................................... 65  
13.1.1  Serious Adverse Events .......................................................................................... 65  
13.1.2  Adverse Events  ....................................................................................................... 65  
13.1.3  Adverse Events of Special Interest  ......................................................................... 66  
13.1.4  New Onset of Chronic Disease  ............................................................................... 67  
13.1.5  Expectedness of an Adverse Drug Reaction  ........................................................... 67  
13.1.6  Initial SAE Reporting by the Investigator  .............................................................. 67  
13.1.7  Follow-up Reporting by the Investigator ................................................................ 68  
13.1.8  Reporting of SAEs Occurring after Surveillance Period or Study Termination ..... 68  
13.1.9  Causal Relationship  ................................................................................................ 68  
13.1.10  Reporting of SAEs to Health Authorities and IRB ................................................. 69  
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 8 of 90 14 INVESTIGATIONAL PRODUCT INFORMATION .......................................................... 69  
14.1  Identity of Investigational Product ................................................................................. 69  
14.1.1  Study Vaccine Composition ................................................................................... 69  
14.2  Active Comparator  ......................................................................................................... 70  
14.3  Preparation and Administration of Study Vaccine ......................................................... 70  
14.4  Preparation, Handling, Storage, and Precautions for Use .............................................. 71  
14.5  Packaging  ....................................................................................................................... 71  
14.6  Labeling .......................................................................................................................... 71  
14.7  Drug Accountability ....................................................................................................... 71  
15 STUDY-SPECIFIC MATERIALS ........................................................................................ 72  
16 ETHICAL ASPECTS  ............................................................................................................ 72  
16.1  Study-Specific Design Considerations ........................................................................... 72  
16.2  Regulatory Ethics Compliance ....................................................................................... 72  
16.2.1  Investigator Responsibilities  ................................................................................... 72  
16.2.2  Independent Ethics Committee or Institutional Review Board .............................. 73  
16.2.3  Informed Consent.................................................................................................... 74  
16.2.4  Privacy of Personal Data  ......................................................................................... 74  
17 ADMINISTRATIVE REQUIREMENTS  ............................................................................. 75  
17.1  Protocol Amendments .................................................................................................... 75  
17.2  Regulatory Documentation ............................................................................................ 75  
17.2.1  Regulatory Approval/Notification  .......................................................................... 75  
17.3  Source Documentation ................................................................................................... 75  
17.3.1  Diary and Memory Aid  ........................................................................................... 76  
17.4  Case Report Form Completion  ....................................................................................... 76  
17.5  Quality Control (Study Monitoring) .............................................................................. 77  
17.6  Quality Assurance .......................................................................................................... 77  
17.7  Record Retention  ............................................................................................................ 77  
17.8  Study Completion/Termination  ...................................................................................... 78  
17.8.1  Study Completion  ................................................................................................... 78  
17.8.2  Study Termination  .................................................................................................. 78  
17.9  Registration of Clinical Studies and Disclosure of Results ............................................ 78  
18 REFERENCES  ...................................................................................................................... 79  
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 9 of 90 19 APPENDICES  ....................................................................................................................... 80  
19.1  Appendix 1 – Sample Ruler to Measure Local Reactions  ............................................. 80  
19.2  Appendix 2 – Burden of Disease Questionnaire ............................................................ 81  
19.3  Appendix 3 – Subject Diary and Memory Aid Sample Pages  ....................................... 83  
 
LIST OF TABLES  
Table 1 Time and Events Schedule: General Information  ............................................................ 21  
Table 2 Time and Events Schedule: Respiratory Illness Onset  .................................................... 23  
Table 3 Summary of Design of Clinical Studies Performed to Date with the Quadrivalent 
Influenza VLP Vaccine  ..................................................................................................... 28  
Table 4 Study Administrative Structure  ....................................................................................... 34  
Table 5 Estimated Blood Volume Drawn ..................................................................................... 44  
Table 6 Severity Grades for Solicited Local and Systemic Reactions  .......................................... 55  
 
  
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 10 of 90 SYNOPSIS  
Sponsor:  Medicago R&D Inc. 
Investigational Product: Plant-derived Quadrivalent VLP Influenza Vaccine 
(Quadrivalent VLP Influenza Vaccine)  
Active Substance(s):  Mix of recombinant H1, H3, and two  B hemagglutinin  proteins 
expressed as virus-like particles ( VLPs) 
Control Product:  Active comparator: Fluarix® Tetra (also named Fluarix® 
Quadrivalent) and/or FluLaval® Tetra ( also named FluLaval® 
Quadrivalent) (both produced and/or distributed by 
GlaxoSmithKline Inc.); 2018-2019 influenza virus strains 
Protocol Title:  A Randomized, Observer-blind, Active Comparator-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunog enicity of a Plant -derived Quadrivalent VLP Influenza 
Vaccine in Adults 65 Years of Age and Older 
Protocol Number:  CP-PRO-QVLP-014 
Development Phase:  Phase 3 
Study Center(s):  The study will be conducted at multiples sites in several countries. 
Study Rationale: The elderly population (65 years of age and older) is at an increased risk of complications due to seasonal influenza infection. This population generally has a poor humoral 
response to immunization  and, due to the combined humoral and 
cell-mediated immune (CMI) response induced by the 
Quadrivalent VLP Influenza Vaccine, it is anticipated  that this 
vaccine can provide greater protection in the elderly. This Phase 3 study is intended to assess the efficacy of the Quadrivalent VLP Influenza Vaccine in elderly adults with no acute or 
evolving medical problems and to support the use of the vaccine in the elderly population. 
Planned Study Period:  Screening and vaccination  will start in  August or September , 
2018. A follow up call will be perfor med at the end of the 
surveillance period , approximately the end of April  2019 (the 
duration of surveillance period may be adjusted, based on the observed epidemiology during the season in participating countries). 
Throughout the influenza season, the number of RT-PCR 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 11 of 90 confirmed influenza cases will be reviewed periodically  by a 
team who will be independent of study conduct and analysis. In 
the event of an insufficient attack rate of confirmed influenza 
(minimum of 19 8 cases), the study will be either continued or 
extended into another season to enrol more subjects and a protocol amendment will be issued to address changes to the enrolment plan.  
Study Objectives  
  Primary Objective:  • To evaluate the efficacy, relative  to an active comparator , of a 
single 30 µg/strain dose of the Quadrivalent VLP Influenza 
Vaccine, against protocol-defined influenza- like illness (ILI) 
caused by any RT-PCR-confirmed influenza case. 
  Secondary Objectives:  Efficacy:  
• To evaluate the efficacy, relative to an active comparator , of a 
single 30 µg/strain dose of the Quadrivalent VLP Influenza 
Vaccine, against laboratory -confirmed protocol-defined 
influenza- like illness (ILI) caused by vaccine- matched strains  
based on seque ntial RT-PCR and antigenic characterization  
for confirmation of vaccine matched and mismatched flu cases; 
• To evaluate the efficacy, relative to an active comparator , of a 
single 30 µg/strain dose of the Quadrivalent VLP Influenza 
Vaccine, against protocol-defined respiratory illness caused 
by vaccine -matched strains  based on sequential RT -PCR and 
antigenic characterization  for confirmation of vaccine 
matched and mismatched flu cases ; 
• To evaluate the efficacy, relative to an active comparator , of a 
single 30 µg/strain dose of the Quadrivalent VLP Influenza 
Vaccine, against RT-PCR-confirmed protocol-defined 
respiratory illness caused by any influenza viral case.  
• To evaluate the efficacy, relative to an active comparator , of a 
single 30 µg/strain dose of the Quadrivalent VLP Influenza 
Vaccine , as measured by the incidence of subjects presenting with symptoms of protocol- defined ILI, regardless of 
laboratory results. 
Safety: 
• To assess the safety and tolerability , relative to an active 
comparator , of a single 30 µg/strain dose of the Quadrivalent 
VLP Influenza Vaccine. 
Immunogenicity: 
• To assess,  in a subset of 420 subjects  (210 subjects per 
treatment group) , the immunogenicity of a single 30 µg/strain 
dose of Quadrivalent VLP Influenza Vaccine and of an active 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 12 of 90 comparator , as measured by  hemagglutination inhibition (HI)  
assay, microneutralization (MN)  assay, and single radial 
hemolysis (SRH) assay against homologous and heterologous 
(HI only) influenza strains . 
The immunogenicity endpoints for all four homologous 
influenza antigens (HI serology) will be compared between 
groups using descriptive statistics .  
  Exploratory Objectives: Efficacy:  
• To evaluate the efficacy, relative to an active comparator , of a 
single 30 µg/strain dose of the Quadrivalent VLP Influenza 
Vaccine, against protocol-defined respiratory illness due to 
mismatch ed influenza strains based on sequential RT- PCR 
and antigenic characterization for confirmation of vaccine 
matched and mismatched flu  cases; 
• To determine the efficacy, relative to an active comparator , of 
a single 30 µg/strain dose of the Quadrivalent VLP Influenza 
Vaccine, as measured by the incidence of subject s presenting 
with symptoms of protocol-defined respiratory illness, 
regardless of laboratory results. 
Safety: 
• To evaluate respiratory illness outcome, occurrences of pneumonia, new onset or exacerbations of cardio- respiratory 
conditions, and health care utilization of subjects administered the Quadrivalent VLP Influenza Vaccine at a dose of 
30 µg/strain relative to subjects administered an active 
comparator . 
Immunogenicity: 
• To assess the CMI response against homologous and heterologous strains of a single 30 µg/strain dose of Quadrivalent VLP Influenza Vaccine and of an act ive 
comparator on Days 0 and 21 in a subset of 420 subjects 
(same subset as the immunogenicity subset ; 210 subjects per 
treatment group ). 
Number of Planned Subjects:  Approximately 12,120 subjects are planned for randomization in 
a 1:1 ratio to receive the Quadrivalent VLP Influenza Vaccine at 
a dose of 30 µg/strain or the active comparator . Prior to 
randomization into the two treatment groups, subjects will be stratified by age into two groups (65 to 74 years of age and 75 
years of age and older) and enrol led in a 2:1 ratio. 
Sample Size The sample size of  approximately  12,120 subjects (6 060 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 13 of 90 Determination : subjects per treatment group) was selected to have 80 % power 
to determine non-inferiority, based on the assumption of 20 % 
vaccine efficacy  (VE), a 2 % or greater  influenza attack rate in 
the active comparator (ARV C) for protocol-defined ILI due to 
RT-PCR-confirmed influenza caused by any viral type/subtype 
and a 10 % dropout rate. Non-inferiority will be concluded if the 
lower bound of the two-sided 95 % confidence interval ( CI) is 
greater than -20 %. 
Please note that the sample size of 12,120 subjects will also provide sufficient power (over 80 %) for the secondary  endpoint 
(protocol-defined respiratory illness  caused by any influenza 
viral type/subtype). 
In the event of an insufficient attack rate of confirmed influenza (minimum of 198 cases), the study will be either continued or extended into another season to enrol more subjects and a protocol amendment will be issued to address changes to the enrolment plan.   
Study Population:  Non-institutionalized  male and female subjects 65 years of age 
and older, with no acute or evolving medical problems and with no clinically significant disease at the time of vaccination , will 
be included in this study. 
Dosage and Administration:  On Day 0, subjects will receive one intramuscular (IM) injection  
into the deltoid region of the arm of 0.5 mL of 30 µg/strain of 
the Quadrivalent VLP Influenza Vaccine or 0.5 mL of  the  
15 µg/strain of the Quadrivalent comparator vaccine (eg: 
Fluarix Tetra /Quadrivalent/
® and/or FluLaval® 
Tetra/Quadrivalent ). 
Study Design:  This is a randomized, observer-blind, active comparator -
controlled, multicenter, Phase 3 efficacy study. 
The influenza strain composition of the vaccines used in this study will be  based on the recommended World Health 
Organization (WHO) strains for vaccinat ion in the 2018-2019 
season in the northern hemisphere. 
Subjects will participate in th is study for approximately eight to 
ten months, during which a first visit will be scheduled on Day 0 
for screening and vaccine administration. A phone contact will be made on Days 1 and 8, specifically for review of the subject’s  
safety and concomitant me dication data . A visit to  the 
investigator site will occur on Day 21 for immunogenicity 
assessments (CMI, HI, MN, and SRH) for a subset of 420 
subjects from pre-defined sites in North America  (210 subjects 
Clinical Pr otocol Version 1.2   CP-PRO -QVLP -014 
Plant -derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 14 of 90 per treatment group) . A final phone contact will be made at the 
end of the study (approximately the end of April 2019) for a 
safety assessment.  
Active and passive surveillance will be conducted in the study from Day 14 until approximately the end of April 2019 (end of the surveillance period ). For passive surveillance, s ubjects will 
be instructed to report symptoms meeting the definition of a new or worsening respiratory illness and ILI. For a ctive surveillance , 
subjects  will be contacted at least once per week and asked 
about symptoms of a new or worsening respiratory illness and 
ILI. The frequency of active surveillance contacts will vary 
slightly with region : 
• North America and Europe: Prior to the start of the influenza season  (the start of influenza season will be determ ined by 
Medicago through local epidemiology and clinical experience), subjects will be contacted at least once per week, using the contact method most likely to be successful (e.g. subject's preferred method [phone, text, e- mail]) . During 
the influenza season, subjects will be contacted a minimum of 
two times per week ; at least one of these weekly contacts will 
be through a scripted telephone call, with the remaining contacts via the method most likely to be successful; 
• Asia: Since there generally is no clearly defined influenza 
season, contacts will be made a minimum of two  times per 
week, with at least one of these weekly contacts through a 
scripted telephone call, with the remaining contacts via the method most likely to be successful (e.g. subject's preferred 
method [phone, text, e- mail]).   
Efficacy Evaluations: Following randomization and vaccination, subjects will report respiratory symptoms from Day 14 until the end of the study (through active or passive surveillance).  Respiratory illness will 
be defined as the occurrence of a new onset of one or more of the following symptoms that persist(s) for or reoccur(s) after a period of at least 12 hours: 
• Sneezing;  
• Stuffy or runny nose (nasal congestion); 
• Sore throat; 
• Cough; 
• Sputum production; 
• Wheezing;  
• Difficulty breathing.  
The site will collect nasopharyngeal (NP) swabs (two per 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 15 of 90 subject per event) for any subject who reports any respiratory 
illness under the following conditions: 
• North America and Europe: only after the start of influenza 
season (as determined by Medicago through local 
epidemiology and clinical experience);  
• Asia: after the start of active and passive surveillance (Day 14 and onwards ). 
The swabs will be collected within 36 hours (preferably within 
24 hours) of the reporting of a respiratory illness . If swabs 
cannot be collected within 36 hours after reporting of the respiratory symptoms, NP swabs should still be collected if the subject still has at least one respiratory illness symptom.  
A swab will be submitted for analysis by multiplex reverse 
transcription polymerase chain reaction ( RT-PCR). If the RT-
PCR result is positive, a dditional testing will be done  (influenza 
virus culture, sero -subtyping , detailed antigenic characterization , 
and vaccine match analysis of the isolates ). 
Any respiratory illness must be followed up for 30 days following the start date  (through the planned active surveillance 
contacts), using a phone script. At the end of the 30-day follow-
up, subjects will complete a disease burden questionnaire (Section 19.2); subjects will be provided with a memory a id 
(Section 19.3) that they can use during the 30 days to facilitate 
accurate reporting.  
Some degree of site investigator discretion will be permitted in defining new episodes (e.g. a non-productive cough and fatigue persisting for ten days from one episode, with a new onset of myalgia, headache, and sore throat would constitute the onset of a valid new episode). 
ILI will also be monitored during the study , but the presence of 
a respiratory illness symptom as described above will be the 
trigger for swab collection . A subject will be considered to have 
ILI if he/she me ets the protocol- defined ILI (≥ 14 days post-
vaccination) conditions:  
• At least one of the following respiratory symptoms: 
• Sore throat; 
• Cough; 
• Sputum production; 
• Wheezing; 
• Difficulty breathing ; 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 16 of 90 AND  
• At least one of t he following systemic symptoms:  
• Fever (defined as temperature > 99.0 °F or > 37.2 °C); 
• Chills; 
• Tiredness; 
• Headache; 
• Myalgia. 
The subjects will also be given a memory aid listing the 
symptoms of respiratory illness and systemic symptoms  and 
contact information for the study site . 
Safety Evaluations: Safety and tolerability endpoints will include immediate 
complaints ( 15 minutes post-vaccination), solicited local and 
systemic reactions (up to seven days post-vaccination), treatment -emergent adverse events (TEAEs) up to Day 21, and 
serious adverse events (SAEs) , adverse events ( AEs) leading to 
withdrawal,  and new onset of chronic diseases (NOCDs) up to 
the end of the surveillance period. A questionnaire will be completed for subjects with respiratory illness regarding disease 
burden.  
Immunogenicity Evaluations: Immunogenicity will be evaluated by the immune response induced in a subset of 420 subjects  (210 from each of the two 
treatment groups ) as measured by the serum HI, MN, and SRH 
antibody titers on Day 0 and Day 21. The number of subjects  in 
each age group (65 to 74 years of age and 75 years of age and older) included in  the immunogenicity analyses will be similar 
in proportion to that of the overall study. 
A blood sample for exploratory CMI analyses will be collected 
on Days 0 and 21 for a subset of 420 subjects (the same subset 
as for HI, MN, and SRH analysis). The North American sites selected for immunogenicity sample 
collection for this subset of 420 subjects will be pre -defined 
prior to study start and will target providing a representative age 
distribution . 
Primary Endpoint : Efficacy : 
Vaccine efficacy (VE), as calculated below  in Statistical 
Methods, determined by differences between subjects who received the Quadrivalent VLP Influenza Vaccine or the active 
comparator vaccine In the occurrences of protocol -defined ILI 
due to RT-PCR-confirmed influenza (≥ 14 days post -
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 17 of 90 vaccination) caused by any influenza  virus.  
Secondary Endpoints:  Efficacy:   
As above: differences between subjects who received the 
Quadrivalent VLP Inf luenza Vaccine or  the active comparator 
vaccine in the occurrence of:  
• RT-PCR-confirmed influenza illnesses (according to protocol 
defined ILI ; ≥ 14 days post- vaccination) caused by influenza 
viral types/subtypes that are matched (and/or antigenically similar) to the strains covered in the vaccine formulation ; 
• RT-PCR-confirmed influenza illnesses  (according to protocol 
defined respiratory illness; ≥ 14 days post-vaccination) caused 
by any influenza viral types/subtypes (matched, mismatched, and un-typed); 
• RT-PCR-confirmed influenza illnesses (according to protocol 
defined respiratory illness; ≥ 14 days post-vaccination) caused by influenza viral types/subtypes that are matched (and/or antigenically similar) to the strains covered in the vaccine formulation; 
• protocol-defined ILI ≥ 14 days post- vaccination  (confirmed or 
not by laboratory testing ). 
Safety: 
• Percentage, intensity, and relationship to vaccination of immediate complaints ( 15 minutes post- vaccination);  
• Percentage, intensity, and relationship to vaccination of solicited local and systemic signs and symptoms (for seven days following study vac cine administration); 
• Percentage, intensity, and relationship of TEAEs for 21 days following study vaccine administration; 
• Occurrences of deaths, SAEs , AEs leading to withdrawal,  and 
NOCDs up to the end of the surveillance period. 
Immunogenicity  (subset of subjects): 
• HI antibody response induced against the homologous and heterologous influenza strains on Days 0 and 21 will be 
assessed in a subset of 420 subjects ( 210 from each of the two 
treatment groups ). HI antibody titers will be analyzed using 
the following parameters: geometric mean titer  (GMT), 
seroconversion ( SC) rate, seroprotection (SP) rate, and 
geometric mean fold rise ( GMFR). The immunogenicity 
endpoints for all four homologous influenza antigens in the VLP vaccine will be compared  between groups using 
descriptive statistics ; 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 18 of 90 • MN antibody response induced by the Quadrivalent VLP  
Influenza Vaccine against the homologous influenza strains 
on Days 0 and 21, in a subset of subjects, will be analyzed 
using the following parameters : GMT, SC rate, and GMFR; 
• SRH antibody response induced by the Quadrivalent VLP 
Influenza Vaccine against the homologous strains on Days 0 and 21, in a subset of subjects, will be analysed using the 
following parameters : geometric mean area (GMA), SC rate, 
SP rate, and GMFR. 
Exploratory Endpoints: Efficacy:  
As above: differences between subjects who received the Quadrivalent VLP Influenza Vaccine or the active comparator vaccine in the occurrence of:  
• RT-PCR-confirmed influenza illnesses (according to protocol 
defined respiratory illness; ≥ 14 days post-vaccination) caused 
by mismatched influenza viral strains; 
• respiratory illnesses ≥ 14 days post-vaccination (confirmed or 
not by laboratory testing ). 
Safety: 
• Information on respiratory illness outcome, occurrences of pneumonia, new onset or exacerbations of cardio- respiratory 
conditions, and health care utilization during the entire trial follow up period. 
Immunogenicity  (subset of subjects): 
• CMI response induced by the Quadrivalent VLP Influenza Vaccine against homologous and heterologous strains on Day 21 (subset of 420 subjects), as measured by the n umber of 
CD4+ T cells expressing each of three functional markers: 
interferon gamma (IFN -γ), interleukin -2 (IL-2), and tumor 
necrosis factor alpha (TNF -α), as well the number of cells 
producing at least one of these cytokines and the number of cells producing two or more of these cytokines. 
Statistical Methods:  Populations: 
Statistical analyses w ill be performed on pre-defined population 
sets (the safety analysis set  [SAS], the full analysis set  [FAS], 
and the per protocol [PP]  set) according to the statistical analysis 
plan (SAP). 
The analyses of all efficacy endpoints will be performed using 
the PP set  and the FAS. The analysis in the PP set will be 
considered the primary analysis for these objectives.  
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 19 of 90 All safety analyses will be performed using the SAS. 
The immunogenicity analyses will be performed using a subset 
of the PP set that includes only subjects with valid 
immunogenicity sample s collected  within the specified time 
window. 
 Statistical Analyses: 
In general, c ategorical data will be summarized using the 
number and percent of subjects in each category and continuous 
data will be summarized using descriptive statistics (mean or geometric mean, median, SD, minimum, and maximum). Immunogenicity endpoints will also be compared between the VLP vaccine group and the active comparator  group. 
Efficacy Analyses: 
For the primary endpoint, VE  will be evaluated as the relative 
risk of subjects vaccinated with a VLP vaccine (30  µg/strain) 
or an active comparator  to develop protocol- defined ILI 
≥14 
days after vaccination  caused by any  RT-PCR-confirmed 
influenza strain .  
 
• VE will be calculated using the following formula: 
VE=(1-ARVV/ARVC)*100 % 
Where: 
ARVV = attack rate in subjects vaccinated with the 
Quadrivalent VLP Influenza Vaccine; and  
ARVC = attack rate in subjects vaccinated with an active 
comparator.  
Non-inferiority will be concluded if the lower limit of the two-
sided 95 % CI  for relative VE is  > -20 % for the primary 
endpoint. If non-inferiority is demonstrated, VE of the VLP vaccine will be tested for superiority over the active comparator  
as an exploratory analysis  (VE for superiority testing will use 
the same definitions as in the primary endpoint). Superiority will 
be concluded if the lower limit of the two -sided 95 % CI for 
relative VE is >  9 % for the primary endpoint. 
VE will also be calculated  for the secondary  and exploratory 
objectives , using other definitions. Non- inferiority will be tested 
using the same criterion as with the primary endpoint; superiority testing will be conducted if non- inferiority is 
concluded (the same criterion as with the primary endpoint will 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 20 of 90 be used for superiority testing) . 
Safety Analyses: 
Safety endpoints will be tabulated, listed, and compared with the 
active comparator  group using descriptive statistics.  
Immunogenicity Analyses: For the immunogenicity analyses, point estimates and two -sided 
95 % CI for serologic and cellular outcomes against homologous 
and heterologous strains will be calculated and  responses in the 
Quadrivalent VLP Influenza Vaccine and active comparator 
vaccine groups will be compared  using descriptive statistics.  
  
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 24 of 90 ABBREVIATIONS  
AE adverse event  
ARVC attack rate in subjects  vaccinated with an active  comparator  
ARVV attack rate in subjects vaccinated subjects  with the Quadrivalent 
VLP Influenza Vaccine  
BMI body mass index  
BP blood pressure  
CBER Center for Biologics Evaluation and Research  
CI confidence interval 
CMI cell-mediated immune (response)  
eCRF electronic case report form  
EMA European Medicines Agency  
FAS full analysis set  
FDA Food and Drug Administration  
GCP Good Clinical Practice 
GMA geometric mean area  
GMFR geometric mean fold r ise or seroconversion factor  
GMT geometric mean titer  
HI hemagglutination inhibition  
HR heart rate 
IB investigator’s brochure  
ICF informed consent form  
ICH International Conference on  Harmonisation  
ILI influenza-like illness  
IM intramuscular  
IEC independent ethics committee  
IRB institutional review board  
MedDRA  Medical Dictionary for Regulatory Activities  
MN microneutralization  
NOCD new onset of chronic disease  
OT oral temperature  
PBMC peripheral blood mononuclear cell  
PP per protocol  
RT-PCR reverse transcription polymerase chain reaction  
SAE serious adverse event  
SAP statistical analysis plan  
SAS safety analysis set  
SAS® Statistical Analysis System® 
SC seroconversion  
SP seroprotection  
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 25 of 90 SRH single radial hemolysis  
TEAE treatment -emergent adverse event  
VE vaccine efficacy  
VLP virus-like particle  
WHO World Health Organization  
USA United States  
 
  
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 26 of 90 1 INTRODUCTION 
Seasonal influenza is a potentially serious infection associated with a wide range of clinical 
outcomes across the entire human lifespan. The influenza virus genome is an eight- segment 
single-stranded RNA with high potential for in situ  recombination and mutations for host 
adaptation. Two segments code for the hemagglutinin and neuraminidase antigens that play an essential role in virus infectivity. At present, 17 h emagglutinin  and ten neuraminidase subtypes 
are known in bird populations and some subtypes routinely circulate in humans, such as the H1N1, H3N2, and B influenza viruses. When a new subtype acquires the capacity for human- to-
human transmission, this can give rise to a major pandemic like the one caused by an H1N1 
strain in 1918 referred to as the Spanish flu. Antibodies that bind to the hemagglutinin  molecule 
can prevent or modify infection and are the basis on which influenza vaccines are formulated every year.  
Despite continuing advances in understanding of the immune response to natural infection and immunization, the disease remains a major cause of morbidity and mortality worldwide. The elderly (≥  65 years) are considered to be among the highest at risk, with recent estimates of 
seasonal flu-related hospitalizations and deaths of 54 % to 70 % and 71 % to 85 %, respectively, 
in this population ( CDC, 2017). In the United States ( USA) alone, influenza is responsible for 
approximately 36,000 deaths per year and the World Health Organization ( WHO) estimates that 
influenza causes three to five million cases of severe illness and 250,000 to 500,000 deaths per year (Palache, 2011 ). Influenza is also responsible for a massive economic burden, with a total 
cost for each winter influenza season estimated at over 87 billion dollars ( Molinari et al., 2007) 
in the USA alone. 
The main strategy for prevention and control of seasonal and pandemic influenza is stil l 
vaccination. In 2012, the Advisory Committee on Immunization Practices  issued the first 
recommendation of national universal seasonal influenza vaccination ( Osterholm et al., 2012). 
Licensure of influenza vaccines is based either on efficacy studies or on surrogate correlates of protection. The latter are primarily based on their ability to induce hemagglutination inhibition (HI) titers. Despite the existence of these surrogate correl ates of protection, recent reviews and 
meta-analyses suggest that the overall efficacy of licensed trivalent vaccines is highly variable 
and depends, among other factors, on the ‘match’ between circulating strains and the strains used 
for vaccine production. One such analysis produced efficacy estimates from 43  % to 89 % in 
well-matched seasons and from 38 % to 85 % in poorly- matched seasons (< 25 % of isolates 
matched the vaccine strains)  (DiazGranados et al., 2012), suggesti ng that there is still great room 
for improvement. 
The elderly population is particularly problematic with respect to vaccine efficacy (VE) . In the 
elderly, the traditionally measured humoral immune response due to immunization may not be 
representative of  VE (McElhaney, 2011), but may confer some degree of protection; a 
retrospective review found that immunization with a well- matched vaccine may provide minimal 
protection against influenza, but may result in a significant imp rovement with respect to seasonal 
flu-related hospital admissions and complications ( Jefferson et al., 2005).  
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 27 of 90 For the 2012-2013 influenza season, VE numbers were particularly discouraging. When 
stratified by age group, the overall VE against influenza A and B viruses ranged from 27 % in 
persons 65 and older to 64 % in children ( six months to 17 years of age ). When specific strains 
and age groups were examined (e.g. H3N2 in the elderly), efficacy estimates could be as low as 
9 % (95 % confidence interval [CI]: -84 % to 55 %). Pre liminary efficacy estimates for the H3N2 
strain in the early 2014-2015 influenza season were even lower: hovering at or even below 0  % 
due to a significant mismatch between vaccine and circulating strain s (Skowronski et al., 2015). 
In the on-going 2017-2018 influenza season, we are again experiencing a low VE  due to 
problems with currently- available vaccines; this time due to the fact that vaccine -strain viruses 
often carry mutations that occur during growth in eggs ( Zost et al., 2017).  
1.1 Quadrivalent VLP Influenza Vaccine  
Medicago R&D Inc. has developed a plant- derived system ( Nicot iana benthamiana) for transient 
expression of two t ype A and two t ype B influenza stra ins to produce the Quadrivalent VLP 
Influenza Vaccine intended for active immunization for the prevention of influenza disease 
caused by the influenza A subtype viruses and type B virus strains covered in the vacci ne. This 
vaccine may be able to address some limitations of the currently licensed vaccines : 
• The hemagglutinin proteins in each monovalent virus- like particle (VLP) is based on the 
genetic sequence of circulating human influenza viruses selected by the WHO; in contrast, 
influenza strains grown in embryonic eggs or tissue culture tend to mutate for optimal 
growth in these substrates; 
• Medicago’s clinical trial program has revealed that plant- derived VLP vaccines induce 
long-lasting and cross -reactive T  cell responses that could be pivotal for protection against 
both matched and diverse influenza strains, particularly in the elderly who often derive significant benefit from vaccination despite little evidence of a humoral response (McElhaney, 2011 ). 
Nicotiana benthamiana is a non- transgenic plant that is a distant wild relative from Australia of 
the tobacco plant, Nicotiana tabacum . The transfer vector used to move targeted DNA constructs 
into the plant cells is the bacterium Agrobacterium tumefaciens . This vector then directs the 
expression of the protein(s) of interest, in this case the hemagglutinin  protein. The hemagglutinin 
proteins are assembled into trimers in the intracellular secretory pathw ay, aligned at the plant 
plasma membrane via a transm embrane domain, and finally bud out of t he plant plasma 
membrane in the form of VLPs. Thus, the viral hemagglutinin  proteins are anchored in a lipid 
bilayer of plant cell origin. The VLPs accumulate in the space between the plasma membrane and plant cell w all. 
1.2 Pre-clinical Studies  
Medicago has conducted several preclinical studies in rats with monovalent, trivalent, and quadrivalent formulations. All strains included in the quadrivalent vaccine are immunogenic at doses ranging from 0.001 to 10 μg in the rat model. 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 28 of 90 No pre-clinical findings have been observed that would suggest the Quadrivalent VLP Influenza 
Vaccine could represent an important risk to human health. Based on pre- clinical results, the 
anticipated benefits from vaccination with the Quadrivalent VLP Influenza Vaccine outweigh the risk. For more comprehensive preclinical information regarding the safety and toxicity of the 
Quadrivalent VLP Influenza Vaccine, refer to the current investigator’s brochure (IB). 
1.3 Clinical Studies  
Under the clinical development program for the Quadrivalent VLP Influenza Vaccine, Medicago has completed five clinical trials to date (CP -Q12VLP-004, CP-Q13VLP-007, CP-Q13VLP-008, 
CP-Q14VLP-009, and CP-Q14VLP-010) and has two trials that are considered to be ongoing 
(CP-PRO
-QVLP-011 [clinical portion complete; statistical analyses and report pending] and CP-
PRO-QVLP-012). Study designs and statuses are summarized in Table 3 . 
Table 3 Summary of Design of Clinical Studies Performed to Date with the Quadrivalent 
Influenza VLP Vaccine  
Study  / Status  Phase  Design  Population  N Treatment groups  
CP-Q12VLP-004 / 
Completed  1-2 Single-center, observer -
blind, randomized, 
dose-ranging, placebo -
controlled study  Healthy adults 18  to 
49 years of age, 
both genders  90 (VLP; ratio 
1:1:1); 
30 (placebo)  3 μg VLP; 
9 μg VLP; 
15 μg VLP; 
placebo 
CP-Q13VLP-007 / 
Completed  2a Multicenter, observer -
blind, randomized, 
dose-ranging, placebo -
controlled study  Healthy adults 18  to 
49 years of age, 
both genders  225 (VLP; ratio 
1:1:1); 
75 (placebo)  15 µg VLP;  
30 µg VLP;  
60 µg VLP;  
placebo 
CP-Q13VLP-008 / 
Completed  2 Multicenter, observer -
blind, randomized, 
dose-ranging, placebo -
controlled study  Healthy subjects of 
50 years of age or 
older, both genders  375 (VLP; ratio 
1:1:1:1:1); 
75 (placebo) 15 µg VLP ; 
30 µg VLP ; 
60 µg VLP ; 
7.5 µg VLP + Alhydrogel®; 
15 µg VLP + Alhy drogel®; 
placebo 
CP-Q14VLP-009 / 
Completed  2 Multicenter, observer -
blind, randomized, dose 
ranging, active -
comparator clinical study Healthy adults of 18 
to 64 years of age, 
both genders  604 (VLP; ratio 
1:1); 
296 (active 
comparator ) 15 µg VLP; 
30 µg VLP; 
15 µg/strain dose of 
FluLaval® Tetra 
CP-Q14VLP-010 / 
Completed  2 Multicenter, observer -
blind, randomized, dose 
ranging, active -
comparator clinical 
study Healthy subjects of 
65 years of age or 
older, both genders  499 (VLP; ratio 
1:1); 
250 (active 
comparator 1 ) 
252 (active comparator 2)  30 µg VLP; 
60 µg VLP; 
15 µg/strain dose of 
FluLaval® Tetra; 
60 µg/strain dose of 
Fluzone® High Dose  
CP-PRO-QVLP-011 / 
Ongoing 3 Multicenter , observer-
blind, randomized , lot 
consistency study  Healthy adults of 18 
to 49 years of age, 
both genders  1200 (VLP; 1:1:1 
ratio to one of 
three lots)  30 µg VLP (three lots)  
CP-PRO-QVLP-012 / 
Ongoing 3 Multicenter, observer -
blind, randomized, 
placebo-controlled 
efficacy study  Healthy adults of 18 
to 64 years of age, 
both genders  ~5000 (VLP); 
~5000 (placebo) 30 µg VLP;  
placebo 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 29 of 90 In the five completed studies, a total of 1793 healthy subjects have received a single dose of the 
Quadrivalent Influenza VLP vaccine: 1 106 subjects from 18 to 64 years of age and 687 subjects 
65 years of age and older. Approximately 6200 subjects have received the VLP vaccine (30 µg/strain) in the two ongoing studies. 
An overview of the available safety and immunogenicity findings from these studies are summarized in Section 1.3.1 and Section 1.3.2, respectively. For detailed information on thes e 
findings, please refer to the current version of the IB. 
1.3.1 Clinical Safety Overview  
This section summarizes the safety data obtained from the five clinical trials performed to date 
(CP Q12VLP-004, CP-Q13VLP-007, CP-Q13VLP-008, CP Q14VLP-009, and CP-Q14VLP-
010); see Table 3 for a description of the basic design of these studies, status, and exposure. No 
deaths were reported for either the adults (N  = 1106) or the elderly subjects (N = 687) 
administered the Quadrivalent VLP Influenza V accine in the five completed studies. In one of 
the ongoing clinical trials (CP -PRO-QVLP-012), two  deaths (cervical spine fracture and lung 
mass) have been reported ; both were considered to be not related to the study vaccine. S ince the 
study is still blinded, the treatment group (30 µg/strain VLP vaccine or placebo ) is not available 
at this time . 
In the five completed trials, a total of 21 serious adverse events ( SAEs) were reported for 
subjects who received the Quadrivalent VLP Influenza V accine: 18 for subjects who received a 
single dose of non-adjuvanted VLP vaccine (all dose levels combined, N = 1642) and three for 
subjects who received a single dose of adjuvanted VLP vaccine (both dose levels combined, 
N = 151). None were considered by the Investigator to be vaccine-related. No subject withdrew from any of the studies due to a treatment -emergent adverse event ( TEAE) and none of the new 
onset of chronic disease s (NOCDs) reported for subjects who received the VLP vaccine were 
considered to be vaccine- related. In the two ongoing trials, no vaccine -related SAEs have been 
reported to date. 
The incidence of local and systemic reactions observed within seven days post- vaccination in the 
five completed studies was consistent with the known safety profile for commercial influenza 
vaccines. The most frequently reported unsolicited TEAEs included nasopharyngitis, upper 
respiratory tract infection, aspartate aminotransferase increased  (minor increase) , headache, and 
oropharyngeal pain; no notable differences in the incidence of these events were observed between the VLP groups and the active comparators or placebo groups. No safety issues and no notable trends were observed with resp ect to vital signs, clinical laboratory, or physical 
examinations in any of the five studies conducted. 
As a precaution, subjects were monitored for TEAEs with a hypersensitivity component 
(reported events were searched using both narrow and broad standardized Medical Dictionary for 
Regulatory Activities (MedDRA
®) queries for a possible hypersensitivity component). Based on 
the data from the five studies conducted to date, there is no evidence of anaphylactic reactions associated with use of the Quadrivalen t VLP Influenza Vaccine in humans: a small number of 
subjects had potential hypersensitivity reactions judged to be related to vaccine administration 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 30 of 90 (no more than 0.3 % of subjects in any given VLP treatment group experienced one of these 
events) and the events were distributed fairly evenly among treatment groups, including the placebo and the active comparator groups. However, since severe reactions are considered to be an important potential risk (based on the theoretical risk that using plants for the production of biotherapeutics may induce hypersensitivity) the sponsor will continue to require that appropriate medical treatment and supervision are available to manage any possible anaphylactic reactions.  
Safety results from the five clinical trials per formed to date show that the Quadrivalent VLP 
Influenza Vaccine was well -tolerated, with a safety profile similar to that of the active 
comparators and to the placebo for systemic reactions and TEAEs. 
1.3.2 Immunogenicity Overview 
This section summarizes the immunogenicity data obtained from the five studies conducted to 
date with adult (up to 64 years of age) and/or elderly (65 years of age and older) populations. Studies CP-Q12VLP-004, CP-Q13VLP-007, and CP-Q14VLP-009 were conducted in an adult-
only population (18 to 49 years for the first two studies and 18 to 64 years for CP-Q14VLP-009), CP-Q13VLP-008 was conducted in a combined adult and elderly population (50 years and 
older), and CP -Q14VLP 010 was conducted in an elderly-only population (65 years of age and 
older). See Table 3 for a description of the basic design of these studies and exposure. 
1.3.2.1 Antibody Response  
Overall, the immunogenicity data from the studies conducted to date show that the Quadrivalent Influenza VLP Vaccine induced a strong antibody response in healthy adults (18 to 64 years); in the elderly, the humoral response appeared lower than in adults (for the VLP as well as the active 
comparator used in both adult and elderly studies). The 30 μg/strain dose level appeared to be the 
lowest dose to be the most consistent in meeting  the Center for Biologics Evaluation and 
Research (CBER) criteria in the adult (18 to 64 years of age population) and the lowest dose to 
be the most comparable with the commercial licensed vaccines. As a result, the 30 μg/strain dose 
level has been selected for evaluation during this Phase 3 efficacy study to be conducted in an elderly population. 
A summary of the Day 21 HI response data for the 30  μg/strain dose level is presented below: 
• In the combined immunogenicity results of the CP-Q13VLP-007 (all subjects) and 
CP-Q13VLP-008 (50 to 64 years old strata), the 30  μg/strain VLP dose level  met the CBER 
criteria for both seroconversion ( SC) rate and seroprotection ( SP) rate against all four 
homologous strains (the sample size of elderly subjects in study CP -Q13VLP-008 was too 
small to allow a thorough evaluation); 
• In study CP-Q14VLP-009, conducted in adults from 18 to 64 y ears of age, the 30 μg /strain 
VLP vaccine met the CBER criteria for both SC rate and SP rate  against all four 
homologous strains tested; 
• In study CP-Q14VLP-010, conducted in elderly subjects 65 years of age and older, the 
humoral response observed was weaker than that observed with the adult population, with  
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 31 of 90 the 30 μg/strain VLP vaccine meeting the CBER SP rate criterion against H1N1 and H3N2 
and the CBER SC rate criterion against only H3N2. However, in this study, none of the treatment groups, including F luLaval
® Tetra and Fluzone® HD, met the CBER criteria for 
SC rate for all of the homologous strains incl uded in the respective vaccines . 
For all of these studies, the HI response may have been underestimated due to the limited availability of assay reagent s unaffected by the use of eggs for production (even when cell- based 
reagents are available, their history often includes an initial expansion in embryonic- eggs). These 
reagents often include mutations of glycosylation site loss in the receptor binding domain, which, 
in turn can affect the assay results, particularly for the B strains. In consequence, the ability of 
the VLP vaccine to elicit an HI response against the B strains may have been underestimated.  
Further assessment of the humoral immune response induced by the VLP vaccine included microneutralization (MN) and single radial hemolysis (SRH) assays, conducted in a subset of 
subjects. For both assays, the VLP vaccine showed notable Day 0 to Day 21 increases in 
geometric mean titer (GMT) against all four of the homologous strains and the overall pattern of 
responses confirm s the 30 μg/strain dose selected for this Phase 3 study. 
In addition to the results above, HI and MN data from the studies conducted to date show that the Quadrivalent V LP Influenza Vaccine also elicits some cross -reactive antibodies against 
heterologous influenza strains  (current IB version).  
1.3.2.2 Cell-mediated Immune Response  
In order to further define immune response induced by the VLP vaccine, the cell -mediated 
immune (CMI) response was measured in a small subset of subjects in the five studies. In spite 
of the small sample sizes, a clear and consistent vaccine -related Day 21 poly-functional CD4+ 
T cell response was observed with the VLP vaccine against all four homologous strains in all studies and in both the adult and elderly populations. With advancing age, these T cell responses were generally much better maintained than antibody responses. Overall, the 30 μg/strain dose level showed the highest response of the VLP vaccines; in contrast, an active comparator (FluLaval
® Tetra) showed a lesser  response against the H1N1 and H3N2 strains. The response 
against the two B strains was similar among treatments . Further, the CMI response induced by 
the VLP vaccines appeared to  be both durable (up to Day 201) and cross- reactive. 
1.4 Overall Rationale for the Study 
The elderly population (65 years of age and older) is at an increased risk of complications due to 
seasonal influenza infection. This population generally has a poor humoral response to 
immunization  and, due to the combined humoral and cell-mediated immune response induced by 
the Quadrivalent VLP Influenza Vaccine, it is hoped that this vaccine can provide greater protection in the elderly. This study is intended to assess the efficacy of the Quadrivalent VLP Influenza Vaccine in non-institutionalized elderly adults with no acute or evolving medical 
problems and to support the licensure of the vaccine in the elderly population. 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 32 of 90 1.5 Benefits and Risk Assessment  
No non-clinical findings suggesting that the administration of the Quadrivalent VLP Influenza 
Vaccine could represent an important risk to human health have been observed.  Based on non-
clinical results, the anticipated benefits from vaccination with the Q uadrivalent VLP Influenza 
Vaccine outweigh the risks.   
During the Phase 3 study CP- PRO-QVLP-014, blood samples will be collected from a subset of 
subjects for humoral immunogenicity analysis.  Since blood sample collection is a minimally invasive procedure and the amount of blood collected will be a relatively small amount, the benefits of obtaining this data outweigh the small level of risk associated with the collection of 
samples that may not require analysis.  
The balance between the anticipated benefit s from vaccination with the Quadrivalent VLP 
Influenza Vaccine versus the potential risk appears favorable, based on the cumulative clinical 
safety data.  Indeed, the Quadrivalent VLP Influenza Vaccine was shown to have a safety profile similar to that of commercially available influenza vaccines, and the immunogenicity data shows 
that the vaccine induces a robust (humoral and cell-mediated) immune response.  The immunogenicity data and safety data collected to date support continuing the clinical developme nt of the VLP Vaccine.  
Since the use of a placebo would raise ethical concerns for individuals 65 years of age and older, who are considered at risk of complications from seasonal influenza, the control selected for the Phase 3 study CP- PRO-QVLP-014 study is an active comparator.  The active comparator will be 
either Fluarix® (produced by GlaxoSmithKline and marketed as Fluarix® Tetra or Fluarix® 
Quadrivalent in different regions ) and/or FluLaval® (produced by ID Biomedical of Quebec and 
distributed by GlaxoSmithKline Inc as either FluLaval® or FluLaval® Quadrivalent in different regions). All a re quadrivalent influenza vaccines licensed in one or more of the targeted 
countries that represent the most widely used dose type of vaccine in elderly subjects.  In 
addition, this type of quadrivalent influenza vaccine has been well -studied and has well -
established immunogenicity, efficacy, and safety profile s for this population.   
A complete risk:benefits assessment is provided in the Investigator’s Brochure (Section 6.1). 
2 OBJECTIVES  
2.1 Primary Objectives  
• To evaluate the efficacy, relative to an active comparator, of a single 30 µg/strain dose of 
the Quadrivalent VLP Influenza Vaccine, against protocol-defined influenza- like illness 
(ILI) caused  by any influenza viral type/ subtype (RT-PCR); 
2.2 Secondary Objectives  
Efficacy:  
• To evaluate the efficacy, relative to an active comparator, of a single 30 µg/strain dose of 
the Quadrivalent VLP Influenza Vaccine, against laboratory-confirmed protocol- defined 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 33 of 90 influenza- like illness (ILI) caused by vaccine- matched strains  (sequential RT -PCR & 
serotyping); 
• To evaluate the efficacy, relative to an active comparator, of a single 30 µg/strain dose of 
the Quadrivalent VLP Influenza Vaccine, against  laboratory-confirmed protocol-defined 
respiratory illness caused by vaccine -matched strains  (sequential RT -PCR & serotyping); 
• To evaluate the efficacy, relative to an active comparator, of a single 30 µg/strain dose of 
the Quadrivalent VLP Influenza Vaccin e, against laboratory-confirmed protocol-defined 
respiratory illness  caused by any influenza viral types/subtypes (matched, mismatched, and 
un-typed) (sequential RT -PCR & serotyping); 
• To evaluate the efficacy, relative to an active comparator, of a single 30 µg/strain dose of 
the Quadrivalent VLP Influenza Vaccine, as measured by the incidence of subjects 
presenting with symptoms of protocol-defined ILI, regardless of laboratory results. 
Safety: 
• To assess the safety and tolerability, relative to an active comparator, of a single 
30 µg/strain dose of the Quadrivalent VLP Influenza Vaccine. 
Immunogenicity: 
• To assess, in a subset of 420 subjects  (210 subjects per treatment group) , the 
immunogenicity of a single 30 µg/strain dose of Quadrivalent VLP Influenza Vaccine, as 
measured by HI assay, MN assay, and SRH  assay against homologous and heterologous 
(HI only) influenza strains. 
2.3 Exploratory Objectives 
Efficacy:  
• To evaluate the efficacy, relative to an active comparator , of a single 30 µg/strain dose of 
the Quadrivalent VLP Influenza Vaccine, against protocol-defined respiratory illness due to 
mismatched influenza strains  (sequential RT -PCR & serotyping); 
• To determine the efficacy, relative to an active comparator , of a single 30 µg/strain dose of 
the Quadrivalent VLP Influenza Vaccine, as measured by the incidence of subjects presenting with symptoms of protocol-defined respiratory illness, regardless of laboratory results. 
Safety: 
• To evaluate respiratory illness outcome, occurrences of pneumonia, new onset or 
exacerbations of cardio -respiratory conditions, and health care utilization of subjects 
administered the Quadrivalent VLP Influenza Vaccine at a dose of 30  µg/strain relative to 
subjects administered an active comparator. 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 34 of 90 Immunogenicity: 
• To assess the CMI response against homologous and heterologous strains of a single 
30 µg/strain dose of Quadrivalent VLP Influenza Vaccine on Days 0 and 21 in a subset of 
420 subjects (same subset as the immunogenicity subset ; 210 subjects per treatment group ). 
3 STUDY ADMINISTRATIVE STRUCTURE  
Table 4 Study Administrative Structure  
Role  Name and Address  
Sponsor  Medicago R&D Inc . 
1020, route de l’Église, bureau 600, 
Sainte-Foy (QC) Canada G1V 3V9  
  
  
4 STUDY DESIGN AND RATIONALE  
4.1 Overview of Study Design 
This randomized, observer-blind, active comparator -controlled Phase 3 study will be conducted 
at multiple sites. The comp osition of the Quadrivalent VLP Influenza Vaccine to be used in this 
study includes a mix of recombin ant H1, H3, and two B hemagglutinin proteins expressed as 
VLPs (see Investigational Product Management Manual) and will be based on the 2018-2019 
recommended WHO strains for vaccination . The composition of the active comparator  is also 
based on the 2018-2019 recommended WHO strains for vaccination. 
Approximately 12,120 non- institutionalized male and female subjects 65 years of age and older 
with no acute or evolving medical problems will be randomized in a 1:1 ratio into one of two 
parallel treatment groups , such that approximately 6060 subjects will receive the Quadrivalent 
VLP Influenza Vaccine at a dose of 30 µg/strain and approximately 6060 subjects will receive  an 
active comparator . Within the two treatment groups, subjects will be randomized  by age into two 
strata (65 to 74 years of age and 75 years of age and older ) in a 2:1 ratio. 
A basic outline of the study design is presented in Figure 1. 
PPD
PPD
Clinical Pr otocol Version 1.2   CP-PRO -QVLP -014 
Plant -derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 35 of 90  
Figure 1 Flowchart of Study Procedures  
Subjects will participate in this study for approximately eight to ten  months, during which a first 
visit will be scheduled on Day 0 for screening and vaccine administration; s ubjects will be 
instructed on how to record reactions, adverse events  (AEs), concomitant medication use, and 
respiratory illness symptoms  in the ir diary and memory aid, as applicable. A phone contact will 
be made on Days 1 and 8, specifically for review of the subject’s safety and concomitant 
medication data. A visit to  the investigator site will occur on Day 21 for a subset of 420 subjects 
from pre -defined sites in North America ( 210 subjects per treatment group) for serology 
sampling and immunogenicity assessments (CMI, HI, MN, and SRH ). A final phone contact will 
be made for a safet y assessment at approximately the end of April 2019 (the end of the 
surveillance period; however, the duration of the surveillance period may be adjusted, based on the observed epidemiology during the season in participating countries). 
Active and passive surveillance will be conducted from Day 14 until approximately the end of 
April 2019 (end of the surveillance period). For passive surveillance, subjects will be instructed 
to report symptoms meeting the definition of a new or worsening respiratory illness and ILI. For 
active surveillance, subjects will be contacted at least once per week and asked  about symptoms 
of a new or worsening respiratory illness and ILI. The frequency of active surveillance contacts 
will vary slightly with region : 
• North America and Europe: Prior to the start of the influenza season (the start of influenza 
season will be determined by Medicago through local epidemiology and clinical experience), subjects will be contacted at least once per week, using the contact m ethod 
most likely to be successful (e.g. subject's preferred method [phone, text, e- mail]). During 
the influenza season, subjects will be contacted a minimum of two  times per week; at least 
one of these weekly contacts will be through a scripted telephone call, with the remaining contacts via the method most likely to be successful; 

Clinical Pr otocol Version 1.2   CP-PRO -QVLP -014 
Plant -derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 36 of 90 • Asia: Since there generally is no clearly defined influenza season, contacts will be made a 
minimum of two  times per week, with at least one of these weekly contacts through a 
scripted telephone call  and the remaining contacts via the method most likely to be 
successful (e.g. subject's preferred method [phone, text, e- mail]) . 
Reports of respiratory illness will be followed up for the collection of information regarding symptoms, concomitant medication use, and disease burden and the collection of two 
nasopharyngeal swabs. For subjects in North America and Europe, swabs will only be collected 
for cases of respiratory illness that occur after the start of the influenza season (as determined by Medicago  through local epidemiology and clinical experience ); for subjects in Asia, swabs will 
be collected for any cases of respiratory illness reported during the surveillance period (Day 14 and onwards). Figure 2  outlines the process to be followed for reports of respiratory illness. 
 
 
Figure 2 Flowchart of Process of Respiratory Illness Report  
Throughout the influenza s eason, the number of laboratory- confirmed influenza cases will be 
reviewed periodically  by selected  members of Medicago and the CRO who will be independent 
of study conduct and analysis . In the event of an insufficient attack rate of confirmed i nfluenza 
(minimum of 198 cases), the study will be either continued or extended into another season to enrol more subjects and a protocol amendment will be issued to address changes to the enrolment plan.  

Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 37 of 90 4.2 Rationale of Study Design 
4.2.1 Randomization 
Randomization will be used to minimize bias in the assignment of subjects to treatment groups, 
to increase the likelihood that known and unknown subject attributes (e.g. demographic and baseline characteristics) are evenly balanced across treatment groups, and to enhance the validity of statistical comparisons across treatment groups.  
4.2.2 Observer- blinding  
Observer-blinded treatment will be used to reduce potential bias during data collection and evaluation of the clinical endpoints. 
4.2.3 Age Group Stratification 
Since age can affect the immune response, subjects will be randomized into each  treatment group 
by age in two strata (65 to 74 years of age and 75 years of age and older) in a 2 :1 ratio in order to 
ensure a representative age distribution  within each treat ment group. 
4.2.4 Dose Selection  
The dose of 30 µg/strain was selected based on data from previous studies as the lowest dose to consistently meet the historical CBER criteria and the dose most comparable with the most 
commonly used commercial licensed vaccines.  
4.2.5 Active Comparator Selection  
The active comparator s (FluLaval
® Tetra/Quadrivalent  and/or Fluarix® Tetra/Quadrivalent  (all 
produced and/or distributed by G laxoSmith Kline Inc) were selected on the basis that these 
products are approved quadrivalent influenza vaccines  and represent the most widely used dose 
in elderly subjects . In addition, these products have been well -studied and have well -established 
immunogenicity, efficacy, and safety profiles for this population.  
4.2.6 Study Duration  
The duration of this study will be approximately eight to ten  months post- vaccination for  all 
subjects in order to capture the maximal number of cases of influenza caused by vaccine-
matched strains in a single influenza season . 
4.2.7 Efficacy  Assessments  
The efficacy endpoint for this study ( ie: sequential reverse transcription polymerase chain 
reaction [RT-PCR] and serotyping to define influenza types/subtypes)  is standard to demonstrate 
influenza VE . The regional differences in the timing of NP swab collection ( for cases of 
respiratory illness that occur after the  start of the influenza season for subjects in North America 
and Europe) was included in order to minimize unpleasant  study procedures that would have 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 38 of 90 minimal benefit [i.e.  prior to influenza season] and to maximize subject compliance during peak 
influenza season in these regions  with well-defined influenza seasons. 
5 STUDY POPULATION 
5.1 Inclusion Criteria  
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study; no protocol waivers are allowed: 
1. Subjects must have read, underst ood, and signed  the informed consent form (ICF) prior to 
participating in the study; subjects must also  complete study -related procedures and 
communicate with the study staff at visits and by phone during the study; 
2. Subject must have a body mass index (BMI) ≤ 35 kg/m2; 
3. Subjects are considered by the Investigator to be reliable and likely to cooperate with the 
assessment procedures and be available for the duration of the study; 
4. Male and female subjects must be 65 years of age  and older at the Screening /Vaccination 
visit (Visit 1);  
5. Subjects must be non- institutionalized (e.g.  not living in rehabilitation centres or old -age 
homes; living in an elderly community is acceptable) and have no acute or evolving medical problems prior to study participation  and no clinically relevant abnormalities that could 
jeopardize subject safety or interfere with study assessments , as assessed  by the Principal 
Investigator or sub- Investigator (thereafter referred as Investigator) and determined by 
medical history, physical examination, and vital signs; 
Note: Subjects with a pre -existing chronic disease will be allowed to participate if the dise ase 
is stable and, according to the Investigator’s judgment, the condition is unlikely to confound 
the results of the study or pose additional risk to the subject by participating in the study. Stable disease is generally defined as no new onset or exacerb ation of pre-existing chronic 
disease three months prior to vaccination. Based on the Investigator’s judgment, a subject 
with more recent stabilization of a disease could also be eligible.  
5.2 Exclusion Criteria  
Subjects who meet any of the following criteria will be excluded from participating in this study; no protocol waivers are allowed: 
1. According to the Investigator’s opinion, history of an ongoing acute or evolving medical or 
neuropsychiatric ill ness. ‘Evolving’ is defined as: 
• Requiring a new medical or surgical treatment during the three months prior to study 
vaccine administration unless the criteria outlined in inclusion criterion no. 5 can be met 
(i.e. the Investigator can justify inclusion based upon the innocuous nature of 
medical/surgical events and/or treatments);  
• Requiring any significant cha nge in a chronic medication (i.e.  drug, dose, frequency) 
during the three months prior to study vaccine administration due to uncontrolled 
symptoms or drug toxicity unless the innocuous nature of the medication change meets 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 39 of 90 the criteria outlined in inclusion criterion no. 5 and is appropriately justified by the 
Investigator. 
2. Any medical or neuropsychiatric condition or any history of excessive alcohol use or drug 
abuse that  would render the subject unable to provide informed consent or unable to provide 
valid safety observations and reporting, including methadone (methadone as treatment for opioid dependence may be acceptable if the subject has been otherwise opioid- free for at 
least three years) ; 
3. Any autoimmune disease other than hypothyroidism on st able replacement therapy 
(including, but not limited to rheumatoid arthritis, systemic lupus erythematosus, Crohn’s disease, type 1 diabetes, and inflammatory bowel disease) or any confirmed or suspected 
immunosuppressive condition or immunodeficiency including known or suspected human immunodeficiency virus (HIV), Hepatitis B or C infection, the presence of lymphoproliferative disease; 
4. Any history of status asthmaticus or ongoing serious problems with asthma, hospitalization 
for asthma control, or recurrent asthma episodes requiring medical att ention in the last three 
years (one or more episodes per year) ; 
5. Administration or planned administration of any non-influenza vaccine within 30 days prior to randomization up to blood sampling on Day 21. Immunization on an emergency basis will be evaluated case- by-case by the Investigator;  
6. Administration of any adjuvanted or investigational influenza vaccine within one year prior to randomization or planned administration prior to the completion of the study; 
7. Administration of any ‘standard’, non- adjuvanted influenza  vaccine (e.g. live attenuated 
trivalent/quadrivalent inactivated influenza vaccine or split triv alent/quadrivalent 
inactivated influenza vaccine administered by intranasal,  intradermal , or intramuscular [IM] 
route) within six  months prior to randomization and up to completion of the study; 
8. Use of any investigational or non-registered product within 30 days or five half-lives, 
whichever is longer, prior to randomization or planned use during the study period. Subjects may not participate in any other investigational or marketed  drug study while participating 
in this study until after the study ; 
9. Treatment with systemic glucocorticoids at a dose exceeding 10 mg of prednisone ( or 
equivalent ) per day for more than seven consecutive days or for ten  or more days in total, 
within one month of study vaccine administration;  any other cytotoxic or 
immunosuppressant drug, or any immunoglobulin preparation within three months of 
vaccination and until the completion of the study. Low doses of nasal or inhaled 
glucocorticoids are allowed. Topical steroids are permitted; 
10. Any significant disorder of coagulation including , but not limited to,  treatment with 
warfarin derivatives or heparin. Persons receiving prophylactic anti- platelet medications 
(e.g. low-dose aspirin [no more than 100 mg/day]), and without a clinically apparent 
bleeding tendency are eligible. Subjects treated with new generation drugs that do not increase the risk of IM bleeding (e.g.  clopidogrel) are also eligible;  
11. History of allergy to any of the constituents of the Quadrivalent VLP Influenza V accine,  
any components of the active comparator quadrivalent vaccine, or tobacco ; 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 40 of 90 12. History of anaphylac tic allergic reactions to plants or plants components (including fruits 
and nuts); 
13. Use of antihistamines within 48 hours prior to study vaccination; 
14. Daily use of large doses of  medication for pain control or inflammation (e.g. opioids, 
nonsteroidal anti- inflammatory drugs [NSAIDs]) . Use of a singular regular  dose either in 
the morning or at bedtime would not be exclusionary; 
15. Use of prophylactic medications (e.g.  acetaminophen/paracetamol, aspirin, naproxen, or 
ibuprofen) within 24 hours of randomization to prevent or pre-empt symptoms due to 
vaccination ; 
16. Planned use of i nfluenza antiviral treatment medication before the collection of NP swabs 
(e.g. oseltamivir, zanamivir, rapivab);  
17. Have a rash, dermatological condition, tattoos, muscle mass, or any other abnormalities at the injection site that may interfere with injection site reaction rating ; 
18. Subjects who have received a blood transfusion within 90 days prior to study vaccination; 
19. Subjects with abnormal vital signs (systolic blood pressure [ BP] ≥ 150 mmHg and/or 
diastolic BP ≥ 95 mmHg for individuals tak ing antihypertensive medication and  
≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg  for individuals not taking antihypertensive 
medication ; heart rate [ HR] ≤ 45 beats/min and ≥ 100 beats/min) evaluated by an 
Investigator to be clinically significant. A subject with abnormal vital signs results may be 
included in the study based on Investigator’s judgment (e.g. a resting HR  ≤ 45 in highly 
trained athletes);  
20. Presence of any febrile illness (including an oral temperature [ OT] ≥ 38.0 ˚C  within 24 
hours prior to vaccination; 
21. Cancer or treatment for cancer within three years prior to study vacci ne administration. 
Persons with a history of cancer who are disease- free without treatment for three years or 
more are eligible. However, i ndividual s with conditions such as  treated and uncomplicated 
basal cell carcinoma o f the skin or non-treated, non- disseminated local prostate cancer may 
be eligible; 
22. Subjects identified  as an Investigator or employee of the Investigat or or clinical site with 
direct involvement in the proposed study, or identified as a n immediate family member 
(i.e. parent, spouse) of the Inves tigator or any employee of Medicago  (or their family 
members) ; 
23. Subjects with a history of Guillain -Barré Syndrome. 
5.3 Prior and Concomitant Therapy  
New or changed medications reported by the subject post-vaccination and through to the end of 
the study will be recorded in the source documents and transcribed in the electronic case report 
form (eCRF ) as a concomitant medication  as per the conditions outlined in the next paragraph. 
Since AEs may be secondary to new medications, the Investigator will explore the reasons for the change or for the new medication intake and document these AEs, if any. 
Concomitant medications must be reported in the eCRF (reason for use, dates of administration, 
dosage, and route) if the use meets the following conditions: 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 41 of 90 • Within 30 days preceding vaccination: an y treatments and/or medications specifically 
contraindicated (e.g.  influenza vaccines, any immunoglobulins or other blood products, or 
any immune modifying drugs, etc.);  
• From randomization to  Day 21, inclusive : any medication (including, but not limited to, 
over-the-counter medicines such as aspirin or antacids), vitamins, and mineral supplements; 
• From Day 22 to the end of the study, inclusive : any concomitant medication(s) 
administered to treat a NOCD (see Section 13.1.4 for definition of NOCD) , SAE, or AE 
leading to withdrawal; any concomitant medication used to treat an AE that occurred before 
Day 21 and that is still being used afterwards (i.e. ongoing use ); and any concomitant 
medications used to treat a protocol-defined respiratory illness or ILI; 
• Any vaccine not foreseen in the study protocol. 
Please refer to the eCRF completion guidelines for details of data entry requirements.  
5.4 Prohibited Therapy  
Please refer to Section 5.2 (exclusion criteria numbers  3, 4, 6, 7, 8, 9, 10, 13 , 15, 16, and 21) for 
details on medications or therapies prohibited prior to randomization, prior to NP swab 
collection,  and/or during the conduct of this study. 
Given that an important obj ective of this study is to evaluate the tolerability of the study vaccine, 
the use of prophylactic medications to prevent or pre-empt symptoms due to vaccination is specifically prohibited up to Day 7 (end of collection of solicited symptoms). A prophylact ic 
medication is a medication administered in the absence of ANY symptom and in anticipation of a reaction to the vaccination (e.g. an antipyretic is considered to be prophylactic when it is given in the absence of fever or any other symptoms, to prevent fever from occurring, vitamins used to boost immune system, etc.). 
The use of influenza antiviral treatment (e.g. oseltamivir, zanamivir, rapivab) is not permitted 
until the NP swabs are collected.  
6 TREATMENT ALLOCATION AND BLINDING  
6.1 Randomization 
Potential s tudy subjects will be screened and assigned a subject number. Once all screening 
procedures, including Day 0 pre-randomization procedures, have been completed and the study eligibility is confirmed by the Investigator, the randomization numbers will be allocated to subjects within the appropriate treatment group by the randomization system. 
Subjects will be randomized to one of two treatment groups, based on a computer- generated 
randomization schedule prepared by or under the supervision of Medicago before the study.  Prior 
to randomization into the two treatment groups, subjects will be stratified  by age into two groups 
(65 to 74 years of age and 75 years of age and older) and enrolled in a 2:1 ratio . 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 42 of 90 Once a randomization number has been assigned, it will not be re-used for any reason. No 
subjects will be randomized into the study more than once. If a randomization number is 
allocated incorrectly, no attempt will be made to remedy the error once the study vaccine has 
been dispensed: the subject will continue on the study with the assigned randomization number 
and associated treatment . The study staff will notify the Sponsor Contact as soon as the error is 
discovered without disclosing the study vaccine administered. Admission of subsequent eligible 
subjects wi ll continue using the next unallocated number in the sequence. 
The randomization number and treatment will be recorded along with the six- digit subject 
number for each subject in the investigational product accountability log. The Investigator will not be provided with randomization codes, but it will be possible to unblind the treatment in an emergency situation.  
6.2 Blinding  
This is an observer-blind study: the subjects, the Investigators, and those responsible for study endpoint evaluations or review or analysis of the study data will not have access to the randomization codes. Any code break will be documented and reported to Medicago (or its designee) in a timely manner. In a medical emergency, the Investigator may unblind the 
treatment for that subject without prior consultation with the Sponsor. In such an event , the 
Investigator will need to contact the responsible Medical Officer as soon as possible after the 
unblinding to discuss the case. 
Since there will be differences in the VLP vaccine and the active comparator  preparations 
(e.g. multi-dose vial versus single-dose syringe, possibly physical appearance) , the site staff 
involved in the preparation and administration of the treatments will not be involved in any 
activity that could introduce a bias , such as the evaluation s of respiratory symptoms, ILI, AEs , or 
reactogenicity of the subjects following vaccination . 
This study is blinded through to the end of the surveillance period of the last subject. The 
randomization code, will not be available during the course of the study to any investigator or any person directly involved in the clinical conduct of the study (including data cleaning and 
data analysis) except the independent team from the contract research organization (CRO) and 
selected individuals from Medicago.  The selected individuals will be independent of study 
conduct and analysis  and will review the number of influenza cases to allow for discussion of the 
clinical data and critical business decisions (e.g. extension of recruitment for another season) prior to study completion. It is anticipated that approximately five people from Medicago and the CRO will have access to the number of cases in a unblinded manner. Also, the central 
laboratories and the staff at the clinical site (except the staff involved in the preparation/administration of the study vaccine, the quality assurance auditor, and  the quality 
control reviewers ) will remain blind ed throughout the entire study duration. 
7 DOSAGE AND ADMINISTRATION 
On Day 0, subjects will receive one IM injection, into the deltoid region of the non-dominant arm (if possible), of their assigned treatment (30 μg/strain of Quadrivalent VLP Influenza 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 43 of 90 Vaccine or  comparator Fluarix® Tetra/Quadrivalent  and/or FluLaval® Tetra/Quadrivalent  
[15 μg/strain] ). The volume of injection will be 0.5 mL for both the VLP vaccine and 
comparators . 
8 SPECIMENS AND CLINICAL SUPPLIES  
8.1 Management of Samples 
Between vaccination and the end of the surveillance period, NP swabs will be collected from any 
subject who reports a new or a worsening respiratory illness (as defined in Section 10.2.1) ; these 
swabs will be collected each time a subject reports such an event within the specified regional 
timeframe (Section 4.1), so multiple collections may be required from some subject s. Two swabs 
will be collected per subject per event. 
On Days 0 and 21, a blood sample for CMI ( peripheral blood mononuclear cell [ PBMC] assay) 
and humoral immunity analysis will be collected for a pre -defined subset of 420 subjects . 
Bioanalysis of the NP swabs and immunogenicity blood samples will be conducted at central laboratories . 
Complete information on the handling, storage, and shipment of all laboratory sampl es will be 
described in the study- specific documentation . 
8.2 Clinical Supplies  
Study center s will be provided with or be responsible for the provision of supplies for NP swabs 
and blood collection and shipment (e.g.  aliquot tubes, aliquot labels, aliquot storage, shipping 
boxes, and accompanying manifests)  as described in the study-specific documentation. Sites will 
be authorized to use their own materials if agreed to by Medicago (or its designee) . 
9 TREATMENT COMPLIANCE  
Treatment compliance is expected to be 100 %, since the study treatments will be administered 
IM at each Investigator site by site staff. In addition, the Investigator or designated study center personnel will maintain a log of all study treatments dispensed and returned during the study. Study drug supplies for each subject will be inventoried and accounted for throughout the study (details will be provided in the study-specific documentation).  
10 STUDY EVALUATIONS  
10.1 Study Procedures  
10.1.1 Overview  
The Time and Events Schedule : General Information (see Table 1) summarizes the frequency 
and timing of scheduled assessments applicable to this study.  
The Time and Events Schedule : Respiratory Illness Onset ( see   
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 44 of 90 Table 2) summarizes the frequency and timing of scheduled assessments associated with the 
onset of a respiratory illness (as defined in Section 10.2.1).  
Most subjects will have no blood sampled; the subset of s ubjects included in the immunogenicity 
analyses and who complete to the Day 21 vis it will have blood volumes drawn of approximately 
120 mL over a period of 21 days ( Table 5). 
Table 5 Estimated Blood Volume Drawn 
Type of Sample  Volume per Sample 
(mL)  Number of Samples per 
Subject  Total Volume of Blood 
per Subject (mL)  
CMI response  50 2* 100* 
HI, MN, and SRH titers  10 2* 20* 
* Day 0 and Day 21 samples to be collected for a pre-defined subset of 420 subjects. 
10.1.2 Screening /Vaccination (Visit 1) 
Emergency equipment must be available on site and appropriate treatment must be instituted as soon as possible in the event of anaphylaxis or any other immediate hypersensitivity reaction. The Investigator will be on- site on vaccine administration days and  for the duration of the 
observation period (minimum of 15 minutes after vaccination) for the last subject dosed on that 
day. The Investigator will be available on call for the remainder of the study. A physician should be immediately available at the clinical site to administer treatment or to apply procedures for any immediate AEs/SAEs.  
10.1.2.1 Prior to Vaccination  
The following procedures will be performed on Day 0 (Visit 1) prior to vaccination: 
• Review and proceed with the signature of the ICF. The Investigator or his/her designee, 
will fully inform the subject of the nature and scope of the study, potential risks and 
benefits of participation, and the study procedures involved and will answer all questions prior to requesting the subject’s signature on the ICF. The subject’s consent must be obtained prior to performing any study- related procedures ; this must be clearly recorded 
and a copy of the signed ICF retained in the source documents. A copy of the ICF must be provided to the subject; 
• Collect and review demographics (gender, date of birth, age, race, and ethnicity) and body 
measurements (BMI, weight  [kg or lbs], and height [cm or inches]) data. BMI is to be 
calculated as body weight (kg) divided by the square of height (m); the BMI result will be 
rounded to one decimal place using the standard convention. For the measurement of body 
weight, subjects will be lightly clothed , without shoes; 
• Collect and review medical history, including the grade of any medical condition s (medical 
conditions are to be graded using the same scale as for AEs; see Section 13.1.2). The 
medical history should record significant problems active at the time of screening and present within the preceding six months. Problems that have been clinically inactive for 
more than  six months preceding screening , but which might alter the subject’s current or 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 45 of 90 future medical management, should also be noted (e.g. known mitral valve prolaps e or a 
remote history of a seizure disorder); 
• Review and record current and previous medication use (up to 30 days prior to study 
vaccine administration) ; 
• Record influenza vaccinations received within 24 months prior to the administration of the 
study vaccine; 
• Perform a vital signs measurement, including resting BP, HR, and OT. OT will be collected 
in degrees Celsius or Fahrenheit using a digital thermometer. The OT measurement should 
not be collected immediately following consumption of a hot or cold beverage or after 
smoking. The BP will be taken after the subject has been in a seated position as per the 
site’s standard procedure. The BP should be taken by cuff (manual or automated are both 
acceptable). BP and HR may be repeated once if judged necessar y. All measurements 
(including any repeats) will be recorded in the source documents. Inclusion of subjects with  
an out-of-range BP or HR measurement will be based on  the Investigator’s judgment; 
• Perform a history- or symptom- directed physical examination  (required if there are medical 
history conditions that can affect subject safety or the evaluation of the study vaccine). The physical exam will be performed by the Investigator;  
• Review the inclusion and exclusion criteria and determine the subject’s eligibility to 
participate in this study. The eligibility must b e confirmed by the Investigator after review 
of all procedures and findings and prior to randomization; 
• If the subject is judged eligible for the study and is still willing to participate in the study, randomize the subject into the study; 
• Only for subjects included in the immunogenicity subset (humoral and cellular immunity assessment ): after confirmation of eligibility and randomization , collect baseline blood 
samples for CMI, HI, MN, and SRH assessments and prepare and store these samples until 
shipment to the analytical laboratory. 
10.1.2.2 Vaccination 
Once all pre- vaccination procedures have been  completed  and subject eligibility determined , the 
study vaccine will be administered (on Day 0) IM into the deltoid muscle of the non-dominant (if 
possible) arm , as described in the Investigational Product Management Manual. In order to 
prevent possible confounding of vaccination site reactions, whenever possible, blood samples will not be collected from the same arm as the one used for vaccination. The arms used, both for 
blood collection and vaccination, will be documented in the source documents. For subjects with BMI <30, a needle of at least 1 inch (25mm) can be used to administer the vaccine. For subject s 
with BMI≥30, a needle of at least 1.5 inches (35mm) must be used to ensure intramuscular (IM) 
delivery.   
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 46 of 90 10.1.2.3 Fifteen Minutes Post -vaccination 
The following safety observation procedures will be performed for all subjects immediately 
following study vaccine a dministration : 
• Subjects will remain in the clinic for at least 15 minutes post-vaccination for observation. 
The observation period will include an assessment of immediate solicited local and systemic reactions. Any unusual signs or symptoms reported during the initial 15 minutes 
post-vaccination will result in  continued close monitoring. Based on their condition, 
subjects may be asked to remain in the clinic for their safety for more than 15 minutes after 
vaccination (the reason will be recorded in the source documents). All data (including the assessment of solicited lo cal and systemic reactions) will be recorded during and after the 
observation period. Refer to Section 10.3.1 for details regarding the assessment of AEs and/or solicit ed local and systemic reactions;  
• During the observation period, subjects will be provided with a measurement device 
template (Section 19.1) for measuring (in mm) solicited local reactions of erythema 
(redness) and swelling  and an oral digital thermometer for recording daily temperature (in 
degrees Celsius  or Fahrenheit ). Subjects will also be provided with a diary and will be 
shown how to enter the ir data in the diary . Each subject  will be provided with the following 
instructions on the measurements they are to make : 
• How to collect his/her OT in degrees Celsius or Fahrenheit with the provided digital 
thermometer : 
• From the evening of Day 0 to the evening of Day 7, the subject will measure his/her OT at approximately the same time each evening and will record the results ; 
• The OT should not be collected immediately following consumption of a hot or cold beverage or after smoking. 
• The subject is  to also take his/her OT if he/she feels feverish and to record the highest 
temperature of the day. In the event that a temperature ≥ 38.0 °C or ≥ 100.4 °F is 
obtained, the subject will be allowed to take over -the-counter antipyretics 
(e.g. acetaminophen/paracetamol, aspirin, naproxen, or ibuprofen) and will be advised 
to increase the frequency  of OT measurements to approximately every four hours, until 
he/she is no longer febrile (fever is defined as a tem perature of ≥ 38.0 ºC or ≥ 100.4 °F ). 
The subject is to document medication intake, which will be reviewed by the site personnel; 
• How to measure any solicited local reactions, including erythema (redness) and swelling diameter at the injection site using the measurement template supplied for this purpose; subjects will also be requested to evaluate pain at the injection site. Local reactions will be assessed every day starting in the evening of Day 0 and up to the evening of Day 7 and 
the results will be re corded. The severity of solicited local reactions will be graded 
according to the Food and Drug Administration ( FDA) Guidance for Industr y: Toxicity 
Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials  (FDA, 2007), as presented in Table 6 . 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 47 of 90 • How to grade, on a daily basis from the evening of Day  0 through to the evening of 
Day 7, each of the solicited systemic reactions  and their severity (as per  the same 
guidance used for solic ited local reactions; see Table 6) (FDA, 2007) and to record the 
worst grade of the day for each of these solicited systemic reaction s. The instructions will 
include how to examine and grade swelling in the neck and axilla and t o record any 
unusual feeling and/or swelling ; 
• Subjects will be a dvised that they will be asked about the occurrence of any symptoms or 
events requiring medical attention and the  use of any concomitant medication during the 
21-day post- vaccination period and  until the end of the surveillance period; 
• Subjects will be instructed to contact the clinical site for any unsolicited AEs and/or 
solicited local and systemic reactions of greater than Grade 2 (moderate). Based on their 
condition, the Investigator may request that the subject return to the clinic for evaluation; 
• Subjects will be a dvised on emergency contact information and instructions for 
contacting study  personnel. Subjects will be advised to immediate ly contact the 
Investigator (or his/her designee)  in the event of an SAE or a medical emergency. 
Subjects will be provided with a phone contact number and be instructed to c all if any 
suspected reaction to the vaccination is felt to be significant or of concern; 
• Subjects will be a dvised to notify their health care professional(s) (e.g. primary care 
physician) that they are participating in a clinical research study of an influenza vaccine;  
• After the 15-minute observation period (allowed window of + 15 minutes) is completed, 
measure vital signs (BP, HR, and OT) as described in Section 10.3.1.3. Any out-of- range 
measurements will be assessed by the Investigator (or his/her designee) and any further action will be determined upon his/her medical decision; 
• Instruct the subjects to perform measurements of local and systemic reactions at approximately the same time each day from Day 0 to Day 7  (preferably in the evening); 
• Provide subjects with a memory aid that they can use to help them accurately report 
respiratory illness and  ILI and safety information  (after Day 21 ); 
• Provide appointments (date and time) for the next planned visit to the clinical site (Day 21) , 
when applicable,  and also for the Days 1 and 8 phone contacts and passive and active 
surveillance p eriods; 
• The subject will be released from the clinical site once all Day 0 post -vaccination 
procedures have been completed and the subject is in stable condition. 
10.1.3 Day 1 and Day 8 (Telephone Contact) 
The following procedures will be performed during the phone contact (acceptable interval of + 1 day for Day  1 and ± 1 day for Day  8): 
• Ask the subjects about any difficulties in recording their data , any change in health, any 
visits to health care facilities  and/or medical practitioners , and any use of concomitan t 
medications. Record the information in the source documents; 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 48 of 90 • For any unsolicited AEs and/or solicited local and systemic reactions of greater than 
Grade 2 (moderate), the Investigator should be informed within 48 hours of the time the clinical site is ma de aware of the event. The Investigator may request that the subject return 
to the clinic for evaluation; 
• Advise subjects to immediately contact the Inv estigator (or his/her designee)  in the event of 
any AE that requires medical attention. Subjects will be  provided with a phone contact 
number and be instructed to call if any suspected reaction to the vaccination is felt to be significant or of concern;  
• Remind the subjects how to measure and record any solicited local and systemic reactions. Subjects should also be reminded to record any changes in health, including changes in AEs and changes in medications; 
• Remind subjects to immediately report any new or worsening respiratory illness, as defined 
in Section 10.2.1. Ensure that subjects have the memory  aid listing the respiratory illness 
symptoms and contact information for the study site; 
• Remind subjects to immediately report any symptoms that meet the definition of an ILI, as 
defined in Section 10.2.1 . Ensure that subjects have the memory  aid listing the symptoms 
of ILI and contact information for the study site;  
• Remind subjects of their next appointment (date and time) for the clinical visit and/or the 
next phone contact. Subjects will also be reminded to record their data in the electronic 
system in a timely manner. 
In the event that  a subject cannot be reached via phone, he/she may be contacted by text message 
or via e-mail (if these contacts are available). However, t he phone should be the initial and 
preferred means of communication. At least three attempts  within allowed time window should 
be made in order to reach the subject. 
10.1.4 Surveillance for R espiratory I llness  
From Day 14 following randomization and vaccination, passive and active surveillance will be 
performed until the end of the end of the surveillance period  (approximately the end of April, 
2019): 
• Passive surveillance: subjects will be instructed to contact the clinical site  within 24 hours 
in case of any new or worsening respiratory illness as defined in Section 10.2.1; 
• Active surveillance: subjects will be contacted  a minimum of  once per week : 
• North America and Europe: Prior to the start of the influenza season (the start of influenza season will be determined by Medicago through local epidemiology and clinical experience), subjects will be contacted at least once per week, using the contact method most likely to be successful (e.g. subject's preferred method [phone, text, e-mail]). During the influenza season, subjects will be contacted a minimum of two times 
per week; at least one of these weekly contacts will be through a scripted telephone call, with the remaining contacts via the method most likely to be successful;  
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 49 of 90 • Asia: Since there generally is no clearly defined influenza season, contacts  will be made a 
minimum of two  times per week, with at least one of these weekly contacts through a 
scripted telephone call  and the remaining contacts via the method most likely to be 
successfu l (e.g. subject's preferred method [phone, text, e- mail]). 
Note: An episode of respiratory illness is considered to extend from the first day of the first 
symptom to the last day of the last symptom. In most cases, a new episode can only begin 
after resolu tion of all symptoms of the previous episode, with a separation of a seven- day 
symptom- free interval between episodes . However, some degree of site investigator discretion 
will be permitted in defining new episodes (e.g. a non-productive cough and fatigue persisting for ten days from one episode, with a new onset of myalgia, headache, and sore throat would constitute the onset of a valid new episode). When Investigator judgement is required in the definition of a new episode of respiratory illness, this judgement should be recorded in the source documents. 
If a subject reports a new or worsening respiratory illness:  
• Collect information regarding the respiratory illness , including all applicable symptoms 
and the onset date:  
• The onset date is defined as the fi rst date when one or more of the qualifying symptoms 
(see above) occurred and persisted for at least 12 hours; 
• Symptoms collected should also include the presence or absence of concurrent systemic 
symptoms (i.e.  fever, feverishness [feeling of warmth], chi lls [shivering], tiredness 
[fatigue], headache, myalgia [muscle aches], nausea, vomiting, or diarrhea ); 
• Collect information on any associated concomitant medication use;  
• Schedule a time when the subject  can return to the clinic site for the collection of N P 
swabs. The NP swabs are to be collected within 36 hours (preferably within 24 hours) 
after reporting of the respiratory symptoms  and according to regional specifications: only 
for cases of respiratory illness that occur after the start of the local influ enza season 
(subjects in North America and Europe) or for any cases of respiratory illness reported 
during the surveillance period (i.e. Day 14 onwards; subjects in Asia); 
Note: If swabs cannot be collected within 36 hours after reporting of the respirator y 
symptoms, NP swabs should still be collected if the subject still has at least one respiratory illness symptom. 
• Respiratory illnesses that start on or after Day 14 will be followed up for 30 days after the illness start date. This follow-up will be conducted via the planned active surveillance 
contacts (telephone and text messaging). All follow -up information should be collected, 
regardless of whether NP swabs could be obtained. Information from more than 30 days from respirato ry illness onset does not need to be collected. As  part of this follow up, the 
following information will be needed: 
• Collect any new information regarding the evolution of the respiratory illness , including 
symptoms and any associated concomitant medicatio n use; 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 50 of 90 • Collect data regarding the end date (if resolved). The end date is defined as the date on 
which the last symptom resolved; 
• Collect information regarding disease burden and health care information: 
• Document whether the illness required consultation a t a clinic or with a general 
practitioner or family physician and if so, how many consultations; 
• Document whether the illness required consultation at an emergency department and if so, how many consultations; 
• Document whether the illness required hospitalization  and if so, for how many days; 
• Document any other medical interventions associated with the illness; 
• Any clinical diagnoses in association with the respiratory illness  (e.g. pneumonia, new 
onset or exacerbations of pre- existing cardio -respiratory conditions ); 
• Document whether the illness resulted in missed work days (if applicable)  and if so, 
how many; 
• Document any  disease sequelae (including long -term); 
• Ask subjects if they have any ILI symptoms, as defined in Section 10.2.1; 
• Ensure subjects have the memory aid listing the symptoms of ILI and contact information 
for the study site ; ensure subjects use the diary or memory aid, as applicable, to record 
reportable i nformation . 
In case a subject cannot be reached via phone, he/she may be contacted by text message or via 
e-mail (if these contacts are available). However, other than for planned text message contacts, 
the phone should be the initial and preferred means of communication  for respiratory illness  
follow-up. 
10.1.5 Day 21 
For all subjects a safety follow -up will be performed on or shortly after Day 21 (- 2/+ 3 days): 
• Review the subject’s safety data and ensure all updates on concomitant medication usage 
and any chang es in the subject’s health (AEs, SAEs, or NOCDs) are recorded 
appropriately; 
• Advise the subjects to immediately contact the Investigator or his/her designee, in the event 
of any AE that requires a visit to an emergency room and/or hospitalization; 
• Ask the subjects to return the ir diary to the clinic site  (the method of return will be defined 
in the study-specific documentation);  
• Remind the subjects of their next phone contact. 
Note: This safety follow -up will be performed during one of the surveillance telephone 
contacts either on or shortly after Day 21. For the subset of subjects participating in the CMI and humoral immunity assessment, this follow-up can be done during the Day 21 visit. 
The following procedures will be performed during the Day 21 (- 2/+  3 days) visit for the subset 
of 420 subjects included in the immunogenicity analyses: 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 51 of 90 • Collect blood samples for CMI, HI, MN, and SRH assessments and prepare and store these 
samples until shipment to the central analytical laboratory;  
• Perform Day 21 safe ty follow-up (as described above) if it is to be done during this visit. 
Note: This visit might replace one of the phone contacts planned for that week.  
10.1.6 End of Surveillance  (Telephone Contact ) 
The following procedures will be performed during the end of surveillance telephone contact (approximately the end of April ; the duration of surveillance period may be adjusted, based on 
the observed epidemiology during the season in participating countries; acceptable interval of 
± 3 days):  
• Record updates on any change in the subject’s health and report any SAEs, NOCDs , or AEs 
leading to subject withdrawal; 
• Record updates on any concomitant medications used to treat AEs that started before Day 
21 and were still ongoing after Day 21, SAEs, AEs leading to withdrawal from the study, or 
NOCDs, as well as prohibited medication use (if any) and any medication taken for a 
respiratory illness ; 
• Confirm that the subject has continued to comply with protocol requirements (e.g. no use of prohibited concomitant medications, reporting of any respi ratory illness or ILI symptoms).  
Any subject who withdraws consent from the study will be asked to participate in the final telephone contact within two weeks of withdrawal, if the subject agrees. 
10.2 Efficacy  
10.2.1 Efficacy Evaluations 
Following randomization and vaccination, subjects will be instructed to report respiratory 
symptoms and symptoms meeting the definition of ILI from Day 14 until the end of the 
surveillance period (passive surveillance). The subjects will be given a memory aid listing the 
symptoms of respiratory illness and ILI and contact information for the study site. During this 
same period, active surveillance will also be performed  to solicit respiratory illness  symptoms  a 
minimum of  once per week: 
• North America and Europe: Prior to the start of the influenza season (the start of influenza season will be determined by Medicago through local epidemiology and clinical experience), subjects will be contacted at least once per week, using the contact method most likely to  be successful (e.g. subject's preferred method [phone, text, e- mail]). During 
the influenza season, subjects will be contacted a minimum of t wo times per week; at least 
one of these weekly contacts will be through a scripted telephone call, with the remai ning 
contacts via the method most likely to be successful; 
• Asia: Since there generally is no clearly defined influenza season, contacts will be made a minimum of two  times per week, with at least one of these weekly contacts through a 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 52 of 90 scripted telephone call and  the remaining contacts via the method most likely to be 
successful (e.g. subject's preferred method [phone, text, e- mail]). 
A respiratory illness will be defined as the occurrence of a new onset of one or more of the 
following symptoms that persist( s) for or reoccur(s) after a period of at least 12 hours: 
• Sneezing;  
• Stuffy or runny nose (nasal congestion); 
• Sore throat; 
• Cough; 
• Sputum production; 
• Wheezing;  
• Difficulty breathing.  
An episode is considered to extend from the first day of the first symptom to the last day of the 
last symptom. A s outlined in Section 10.1.4, in most instances a new episode can only begin 
after resolution of all symptoms of the previous episode, with a separation of a seven- day 
symptom- free interval between episodes.  
Within 36 hours (preferably within 24 hours) after the reporting of a respiratory illness, the clinic 
site will collect nasopharyngeal (NP) swabs from the sub ject (two per subject per event)  if the 
start of the respiratory illness falls in  the indicated regional timeframe: 
• North America and Europe: after the start of influenza season;  
• Asia: after the start of active and passive surveillance (Day 14 and onwards). 
The swabs must be collected prior to the use of any influenza antiviral treatment medication (e.g. oseltamivir, zanamivir, rapivab). If the respiratory illness starts prior to Day 14, swabs are 
not to be collected, even if symptoms persist beyond Day 14. 
A swab will be submitted for analysis by multiplex RT-PCR. In the event of a positive RT- PCR 
result (positive for A or B strains), additional testing will be done  to attempt to isolate the virus 
or for additional cell-culture testing (typing, subtyping, and strain identification and genetic 
sequencing using H I assay against a panel of known standard ferret reference antisera to different 
viral strains) to determine if the virus detected is matched or similar to any of the strains covered 
in the vac cine formulation for the respective season . A positive RT- PCR result will be 
considered a laboratory -confirmed case of influenza.  The NP swabs  will be analyzed in a central 
laboratory; information on processing and the central laboratories will be provided in the study-specific documentation . 
Any respiratory illness must be followed up for 30 days following the start date; this follow up will be conducted via the planned active surveillance contacts (telephone and text messaging) , 
using a script. At the end  of the 30-day follow up, a questionnaire regarding disease burden due 
to the respiratory illness will be completed (Section 19.2); subjects will be provided with a 
memory aid (Section 19.3) for use over the 30 da ys, to facilitate accurate reporting at the end of 
the follow-up period. 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 53 of 90 ILI will also be monitored during this study. A subject will be considered to have protocol-
defined ILI if the following two conditions are both met between Day 14 and the end of the surveillance period : 
• He/she has at least one of the following pre-defined respiratory symptoms: 
• Sore throat; 
• Cough; 
• Sputum production; 
• Wheezing; or 
• Difficulty breathing;  
AND  
• He/she has at least one of the following systemic symptoms: 
• Fever (defined as a temperature > 37.2  °C or > 99.0 °F ); 
• Chills; 
• Tiredness;  
• Headache; or  
• Myalgia. 
In addition, information on the following uncommon ILI symptoms will be collected for any subjects with a protocol-defined respiratory illness during the surveillance period: nausea, vomiting, and  diarrhea. 
10.2.2 Efficacy  Endpoints  
10.2.2.1 Primary Endpoint  
Vaccine efficacy  will be defined  as per the applicable regulatory region- specific case definition , 
as follows: 
• Occurrences of protocol-defined ILI due to laboratory-confirmed influenza (≥ 14 days post-
vaccination) caused by any influenza viral type/subtype ( RT-PCR). 
10.2.2.2 Secondary Endpoints  
• Occurrences of laboratory -confirmed influenza illnesses (according to protocol defined ILI; 
≥ 14 days post- vaccination) caused by influenza viral types/subtypes that are matched 
(and/or antigenically similar) to the strains covered in the vaccine formulation (sequential RT-PCR & serotyping);  
• Occurrences of laboratory -confirmed influenza illnesses (according to protocol defined 
respiratory illness ; ≥ 14 days post- vaccination) caused by any influenza viral 
types/subtypes (matched, mismatched, and un- typed) (sequential RT -PCR & serotyping); 
• Occurrences of laboratory -confirmed influenza illnesses  (according to protocol defined 
respiratory illness; ≥ 14 days post- vaccination) caused by influenza viral types/subtypes 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 54 of 90 that are matched (and/or antigenically similar) to the strains covered in the vaccine 
formulation  (sequential RT -PCR & serotyping); 
• Occurrences of protocol-defined ILI ≥ 14 days post-vaccination (confirmed or not by laboratory testin g). 
Exploratory Endpoints 
• Occurrences of laboratory -confirmed influenza illnesses ( according to protocol defined 
respiratory illness; ≥ 14 days post- vaccination) caused by mismatched influenza viral 
strains (sequential RT -PCR & serotyping); 
• Occurrences of respiratory illnesses ≥ 14 days post- vaccination (confirm ed or not by 
laboratory testing ). 
10.3 Safety  
10.3.1 Evaluations 
Safety and tolerability will be evaluated by solicited local and systemic reactions (immediate complaints within 15 minutes post- vaccination and solicited reactions up to seven days post-
vaccination), unsolicited AEs up to 21 days post-vaccination, and SAEs and NOCDs, and AEs leading to withdrawal up to the end of the surveillance period. In addition, events will be 
monitored for a possible hypersensitivity component, from all reported events during the study 
(collected AEs, SAEs, NOCDs, and AEs leading to withdrawal). 
10.3.1.1 Solicited Local and Systemic Reactions  
Subjects will be monitored for both solicited local reactions (erythema, swelling, and pain at the 
injection site) and solicited systemic reactions ( fever, headache, fatigue, muscle aches, joint 
aches, chills, a feeling of general discomfort, swelling in the axilla, and swelling in the neck) 
from the time of vaccina tion through Day 7. While the subjects remain  in the clinic following 
vaccine administration, staff will monitor  them for local and systemic reactions; after release 
from the clinic facility, from the evening of Day 0 to the evening of Day 7, subjects will measure and record their local and systemic reactions in their diary. 
The intensity of the solicited local and systemic reactions will be graded as: mild (1), moderate (2), severe (3), or potentially life threatening (4) (please refer to Table 6). Their causal 
relationship with the study vaccine will be assessed by the Investigator (definitely not related, probably not related, possibly related, probably related or definitely related); see Section 13.1.9 
for the definition of the causal relationships. 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 55 of 90 Table 6 Severity Grades for Solicited Local and Systemic Reactions  
Symptoms  Severity  
None  Grade 1  
(Mild)  Grade 2 (Moderate)  Grade 3 (Severe)  Grade 4 
(Potential ly life-
threatening)  
Injection Site Reactions (Local Reactions)  
Erythema (redness)  < 25 mm 25 - 50 mm 51 - 100 mm > 100 mm Necrosis or 
exfoliative dermatitis  
Swelling  < 25 mm 25 - 50 mm and 
does not interfere with activity  51 – 100 mm or 
interferes with activity > 100 mm or 
prevents daily activity  Necrosis 
Pain  None Does not 
interfere with activity Repeated use of 
non-narcotic pain 
reliever for more 
than 24 hours or 
interferes with 
activity Any use of 
narcotic pain 
reliever or prevents daily activity Results in a visit 
to emergency room (ER) or hospitalization  
Solicited Systemic Reactions  
Fever (ºC or ºF ) 
 < 38.0 ºC 
< 100.4 ºF 38.0 - 38.4 ºC 
100.4 - 101.1 ºF 38.5 - 38.9 ºC 
101.2 - 102.0 ºF 39.0 - 40.0 ºC 
102.1 - 104.0 ºF > 40.0 ºC 
> 104.0 ºF 
Headache  None No interference 
with activity  Repeated use of 
non-narcotic pain 
reliever for more than 24 hours or 
some interference with activity  Significant; any 
use of narcotic 
pain reliever or 
prevents daily activity Results in a visit 
to emergency 
room (ER) or 
hospitalization  
Fatigue  None No interference 
with activity  Some interference 
with activity  Significant; 
prevents daily activity  Results in a visit 
to emergency room (ER) or hospitalization  
Muscle aches  None No interference 
with activity  Some interference 
with activity  Significant; 
prevents daily 
activity  Results in a visit 
to emergency room (ER) or 
hospitalization  
Joint aches, chills, 
feeling of general 
discomfort or 
uneasiness (malaise), swelling in the axilla, swelling in the neck None No interference 
with activity  Some interference 
with activity not 
requiring medical 
intervention  Prevents daily 
activity and 
requires medical 
intervention  Results in a visit 
to emergency 
room (ER) or 
hospitalization  
10.3.1.2 Adverse Events  
All spontaneous AEs occurring within 21 days after vaccination will be reported in the “Adverse 
Event” screen in the subject’s eCRF, irrespective of intensity or whether or not they are 
considered to be vaccination-related. Thereafter, from Day 22 to the end of the surveillance period, SAEs, AEs leading to withdrawal, and NOCDs will be monitored and reported in the 
eCRF. 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 56 of 90 The intensity of AEs will be graded as: mild (1), moderate (2), severe (3) or potentially life 
threatening (4) , according to the FDA Guidance for Industry ( FDA, 2007). Their causal 
relationship with the study vaccine will be assessed by the Investigator (definitely not related, probably not related, possibly related, probably related or definitely related); see Section 13.1.9 for a definition of these causal relationships. 
10.3.1.3 Vital Signs  
Vital signs measurements (resting BP, HR, and OT) will be performed as part of screening 
procedures (prior to eligibility assessment on Day 0) and after  the post-vaccination surveillance 
period. 
OT will be collected in degrees Celsius or Fahrenheit using a digital thermometer  provided by 
the Sponsor. The OT measurement should not be collected immediately following consumption 
of a hot or cold beverage or after smoking. 
BP will be taken after the subject has been in a seated position as per the site’s standard 
procedure. BP should be taken by cuff (manual or automated are both acceptable). BP and HR 
may be repeated once if judg ed necessary. All measurements (including any repeats ) will be 
recorded in the source documents. 
10.3.1.4 Physical Examinations 
If applicable, a history- or symptom- directed physical examination will be performed by the 
Investigator as part of screening procedures (prior to eligibility assessment on Day 0).  
10.3.2 Safety Endpoints  
10.3.2.1 Secondary Endpoints  
• Percentage, intensity, and relationship to vaccination of immediate complaints (15 minutes 
post-vaccination);  
• Percentage, intensity, and relationship to vaccination of solicited local and systemic signs 
and symptoms (for seven days following study vaccine administration); 
• Percentage, intensity, and relationship of TEAEs for 21 days following study vaccine administration; 
• Occurrences of deaths, SAEs, AEs leading to withdrawal, and NOCDs up to the end of the 
surveillance period . 
10.3.2.2 Exploratory Endpoint 
• Information on respiratory illness outcome, occurrences of pneumonia, new onset or 
exacerbations of cardio -respiratory conditions, and health care utilization during the entire 
trial follow up period. 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 57 of 90 10.4 Immunogenicity  
10.4.1 Immunogenicity Evaluations 
Immunogenicity will be evaluated by the humoral immune response (HI, MN, and SRH assays) 
and the CMI response induced in subjects on Days 0 and 21 in  a subset of 420 subjects ( 210 
from each treatment group ) from selected sites.  The North American sites selected for this subset 
of 420 subjects will be pre -defined prior to study start and will target providing a representative 
age distribution. The number of subjects in each age gr oup (65 to 74 years of age and 7 5 years of 
age and older) included in the immunogenicity analyses will be similar in proportion to that of the overall study. 
The blood s amples for immunogenicity will be analyzed in one or more central laboratories; 
information on processing and the central laboratories will be provided in the study- specific 
documentation. 
10.4.2 Immunogenicity Endpoints  
Unless otherwise mentioned, point es timates and 95% CI will be calculated for all The 
immunogenicity endpoints and responses in the Quadrivalent VLP Influenza Vaccine 
recipients will be compared with  the active comparator group using descriptive statistics.   . 
10.4.2.1 Secondary Endpoints  
• HI antibody response induced against the homologous and heterologous influenza strains 
on Days 0 and 21 in a subset of 420 subjects  (210 from each of the two treatment groups). 
HI antibody titers will be analyzed as follows: 
• GMT of HI antibody on Days 0 and 21; 
• SC rate: the proportion of subjects in a given treatment group with either a ≥ 4-fold increase in reciprocal HI titers between Day 0 and Day 21 or a rise of undetectable HI titer (i.e. < 10) pre -vaccination (Day 0) to  an HI titer of ≥ 40 on Day 21; 
• SP rate: the proportion of subjects in a given treatment group attaining a reciprocal HI 
titer of ≥ 40 on Day 21 (the percentage of vaccine recipients with a serum HI titer of at least 1:40 following vaccination); 
• Geometric mean fold rise (GMFR): the geometric mean of the ratio of GMTs (Day 
21/Day 0). 
• MN antibody response induced by the Quadrivalent VLP Influenza Vaccine against the 
homologous influenza strains on Days 0 and 21, in the subset of subject s, will be analysed 
as follows: 
• GMT of MN antibody on Days 0 and 21; 
• SC rate on Day 21 (as defined above for HI); 
• GMFR (Day 21/Day 0). 
• SRH antibody response induced by the Quadrivalent VLP Influenza Vaccine against the 
homologous strains on Days 0 and 21 in a subset of subjects, will be analysed as follows: 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 58 of 90 • Geometric mean area (GMA) of SRH antibody on Days 0 and 21; 
• SC rate: proportion of subjects in a given treatment group showing at least 50  % increase 
in GMA between D ays 0 and 21; 
• SP rate: the proportion of subjects in a given treatment group attaining an area diameter 
≥ 25 mm2 following vaccination (Day 21); 
• GMFR: the geometric mean of the ratio of GMA  (Day 21/Day 0).  
10.4.2.2 Exploratory Endpoint 
• CMI response induced by the Quadrivalent VLP Influenza Vaccine against homologous 
and heterologous strains on Day 21 (subset of 420 subjects), as measured by the number of 
CD4+ T cells expressing each of three functional markers: interferon gamma (IFN -γ), 
interleukin -2 (IL-2), and tumor necrosis factor alpha (TNF-α), as well the number of cells 
producing at least one of these cytokines and the number of cells producing two or more of 
these cytokines. 
11 SUBJECT COMPLETION/ WIT HDRAWAL  
11.1 Temporary Contraindications 
Some exclusion criteria that render subjects ineligible for the study may be temporary in nature: 
• Temperature ≥  38.0 ºC or ≥ 100.4 ºF within 24 hours prior to randomization; 
• Acute cold symptoms such as upper respiratory tract infection symptoms, with or without 
fever, that resolve at least 48 hours prior to randomization. 
If, on the day of Screening, a subject is considered ineligible due to one of these “temporary 
contraindications”, the subject should be considered as a screening failure. Following the 
resolution of such conditions, a subject may be rescreened (including the informed consent 
process) under a new number and, if considered eligible by the Investigator, be enrolled in the 
study. 
11.2 Screening Failures  
Screening  failures are subjects who have signed the study -specific ICF but are not eligible for 
enrolment (subjects who are not vaccinated ), due to failure on one or more of the inclusion or 
exclusion criteria or because the subject withdrew consent prior to randomization. Eligible/not 
treated subjects are subjects that have signed the ICF and are eligible for enrolment, but were either not randomized or randomized and not treated. 
Recording of screening failures and eligible/not treated subjects will be carried out  in the study 
records maintained at the participating clinical sites. Neither of these subject classes will receive 
a safety follow -up. 
Any subjects who are considered as a screening failure should be indicated as such. A screening failure subject can be rescreened (under a new number). If the subject is rescreened, a new subject number will be allocated.  
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 59 of 90 11.3 Removal of Subjects from Treatment or Assessment  
Subjects will be advised that they are free to withdraw from the study at any time without 
prejudice to their future medical care by the physician or the institution. Subjects who withdraw or are withdrawn from the study after vaccination will not be replaced.  
Every reasonable effort will be made to ensure that each subject complies with the protocol and completes all study visits. However, a subject may withdraw or be withdrawn from participation if: 
• The subject withdraws consent; 
• The subject displays non- compliance to the terms of their participation in the clinical study 
(based on Investigator’s or Medi cago’s [or its designee’s] opinion); 
• Safety reasons as judged by the Investigator and/or Medicago  (or its designee) ; 
• Medicago or the regulatory authority(ies) terminates the clinical study.  
Withdrawal subjects will be those who leave the study before the end of the surveillance period, 
for whatever reason; withdrawal subjects will not be replaced. Any subject who withdraws 
consent from the study will be asked to participate in the final telephone contact within two weeks of withdrawal  and at the end of the surveillance period, if the subject agrees. The 
procedures performed for the final assessment will comprise those for the end of surveillance telephone contact , if permitted by the subject. All withdrawal subjects must be reported to 
Medicago  (and/or its designee) . The reason for withdrawal should be documented in the 
subjects’ records and in the appropriate section of the eCRF. The eCRF must be completed up to 
and including the time of the drop- out/final assessment.  
11.3.1 Follow- up of Discontinuations  
All subjects who receive a study vaccine will be followed for safety until the end of the 
surveillance period, if permitted by the subject.  
11.3.2 Lost to Follow- up Procedures  
Every attempt will be made to contact study subjects who are lost to follow -up. At least three 
contacts will be attempted and recorded in the source documents. As a last resort, one registered letter requesting contact with the site will be sent to any subject with whom the clinic staff no longer has contact. All attempts at contact will be documente d in the subject’s source documents. 
11.4 Interruption of the Study  
The Investigator (in consultation with Medicago [or its designee]), Medicago, or Regulatory Authorities may interrupt or terminate this study for any reason. The Investigator will 
immediately, on discontinuance of the clinical study at the clinical site, inform both the study 
subjects and the i nstitutional review board (IRB) responsible for the study of the discontinuance, 
provide them with reasons for the discontinuance and advise them in writing of any potential health risks to the subjects themselves or to other persons. It is Medicago’s (or its designee’s) 
responsibility to report discontinuance of the study to the local regulatory agencies within the 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 60 of 90 appropriate timeframe, providing the m with the reasons for the discontinuance and advising 
them in writing of any potential health  risks to the study subjects or to other persons. Medicago 
(or its designee) must then inform the Investigator that the appropriat e notifications were done. 
12 STATISTICAL METHODS  
A general description of the statistical methods used to analyze the efficacy, safety , and 
immunogenicity  data is outlined below. Complete details will be provided in the statistical 
analysis plan (SAP), which will be finalized prior to data base lock. 
12.1 Analysis Populations 
12.1.1 Safety Analysis Set 
The safety analysis set (SAS) is defined as all su bjects who received  either the Quadrivalent VLP 
Influenza Vaccine or the active comparators . All safety analysis will be performed using the 
SAS, accordin g to the treatment the subjects actually received.  
12.1.2 Full Analysis Set  
The full analysis set (FAS) will consist of the subset of subjects in the SAS who were 
successfully contacted at least once during the surveillance period . Subjects who received the 
wrong treatment will be analyzed as randomized. 
12.1.3 Per Protocol Set  
The per protocol ( PP) set will consist of the subjects who participated in the study until at least 
the end of the peak period (approximately the end of February for Europe and North America) or 
for at least five months or until the end of the surveillance period (other countries) ; had no major 
protocol deviations related to subject eligibility,  the ability to develop a valid immune response, 
prohibited medication use, or the efficacy analyses ; and who received the VLP vaccine or the 
active comparator . Major protocol deviations will be identified and documented during a blinded 
data review prior to database lock and confirmed at the time of database lock. The PP set  will be 
the primary analysis population for the efficacy and immunogenicity endpoints. Subjects who 
received the wrong treatment, but for whom the treatment received can be unequivocally confirmed, will be analyzed as treated, provided they have no other deviations that compromise their data.  
The analyses of all efficacy endpoints will be performed using the efficacy PP population and the FAS population. 
The immunogenicity PP set will consist of the subset of subjects who participated in the 
immunogenicity  portion of the study, who had a Day 21 i mmunogenicity sample collection; who 
had no major deviations related to subject eligibility, the ability to develop a valid immune response, prohibited medication use, or the immunogenicity analyses; and who received the vaccine or the active comparator . Subjects who received the wrong treatment, but for whom the 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 61 of 90 treatment received can be unequivocally confirmed, will be analyzed as treated, provided they 
have no other deviations that compromise their data. 
12.2 Sample Si ze Determination  
The sample size of approximately 12,120 subjects ( 6060 subjects per treatment group) was 
selected to have 80 % power to determine non- inferiority,  based on the assumption of 20 % VE , 
a 2 % or greater attack rate in the active comparator (A RVC) for protocol-defined ILI caused by 
any influenza viral types/subtypes, and a 10 % dropout rate. Non -inferiority will be concluded if 
the lower bound of the two-sided 95 % CI is greater than -20 %. 
In the event of an insufficient attack rate of confirmed influenza (minimum of 198 cases), the 
study will be either continued or extended into another season to enrol more subjects and a 
protocol amendment will be issued to address changes to the enrolment plan. 
12.3 Efficacy  Analyses 
Efficacy endpoints are described in Section 10.2.2. 
All descriptive and inferential statistical analyses will be performed using Statistical Analysis 
System® (SAS®) software (version 9.3 or higher). Details of the statistical analyses will be  
provided in the SAP, finalized prior to unblinding subject treatment assignment and database lock. Summary tables will present data for the overall population and for each age s tratum, as 
applicable.  
12.3.1 Analysis of Primary Endpoint  
The primary efficacy endpoints are defined in Section 10.2.2.1. 
For the primary endpoint, VE will be evaluated as the relative risk of subjects vaccinated with 
Quadrivalent VLP Influenza V accine (30  µg/strain) or an active comparator to develop protocol-
defined ILI as a result  of laboratory-confirmed infect ion with any influenza virus ( RT-PCR) ≥14  
days after vaccination  
VE will be calculated using  the following formula: 
VE=(1-ARV
V/ARVC)*100 % 
Where: 
  ARV V = attack rate in subjects vaccinated with the Quadrivalent VLP Influenza Vaccine; and  
  ARV C = attack rate in subjects vaccinated with an active comparator. 
Non-inferiority will be concluded if the lower limit of the two -sided 95 % CI for relative VE is 
> -20 % for the primary endpoint. If non- inferiority is demonstrated, VE of the VLP vaccine will 
be tested for superiority over the active comparator  as an exploratory analysis  (VE for superiority 
testing will use the same definitions as in the primary endpoint). Superiority will be concluded if the lower limit of the two -sided 95 % CI for relative VE is > 9 % for the primary endpoint. 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 62 of 90 12.3.2 Analysis of Secondary Endpoints  
The secondary efficacy endpoints are defined in Section 10.2.2.2. 
VE will be calculated  for the following endpoints , using the same formula indicated  for the 
primary efficacy analys is: 
• The relative risk of subjects vaccinated with a VLP vaccine (30  µg/strain) or an active 
comparator to develop protocol-defined ILI as a result of laboratory-confirmed influenza 
infection ≥ 14 days after vaccination with a viral type/subtype that is  matched and/or 
antigenically similar to the strains covered in the vaccine formulation  (sequential RT-PCR 
& serotyping); 
• The relative risk of subjects vaccinated with a VLP vaccine (30  µg/strain) or an active 
comparator to develop a respiratory illness caused by a laboratory- confirmed  influenza 
strain ≥14 days after vaccination caused by a viral type/subtype that is  matched and/or 
antigenically similar to the strains covered in the vaccine formulation)  (sequential RT- PCR 
& serotyping); 
• The relative risk of subjects vaccinated with a VLP vaccine (30  µg/strain) or an active 
comparator to develop a respiratory illness  caused by any laboratory-confirmed influenza 
strain ≥ 14 days after vaccination ( RT-PCR & serotyping); 
• The relative risk of subjects vaccinated with a VLP vaccine (30  µg/strain) or an active 
comparator to present with ILI ≥14 days after vaccination, regardless of the laboratory 
results (i.e. the proportion of subjects with at least one episode of protocol- defined ILI).  
Non-inferiority will be tested using the same criterion as with the primary endpoint; superiority 
testing will be conducted if non- inferiority is concluded (the same criterion as with the primary 
endpoint will be used for superiority testing). 
12.3.3 Analysis of Exploratory Endpoints 
The exploratory efficacy endpoint s are defined in Section 10.2.2.3. 
VE will be calculated for the following endpoints, using the same formula indicated for the 
primary efficacy analysi s: 
• The relative risk of subjects vaccinated with a VLP vaccine (30  µg/strain) or an active 
comparator to become infected with a protocol-defined respiratory illness caused by a 
laboratory-confirmed, mismatched influenza strain ≥14 days after vaccination (i.e.  the 
proportion of subjects with one or more episode of respiratory illness  shown to be caused 
by viral types/subtypes that are not antigenically similar to the strains covered in the 
vaccine formulation)  (sequential RT- PCR & serotyping) ; 
• The relative risk of subjects vaccinated with a VLP vaccine (30 µg/strain) or an active 
comparator to present with respiratory illness symptoms ≥14 days after  vaccination 
regardless of the laboratory results  (i.e. the proportion of subjects with at least one episode 
of protocol-defined respiratory illness). 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 63 of 90 Non-inferiority will be tested using the same criterion as with the primary endpoint; superiority 
testing will be conducted if non- inferiority is concluded (the same criterion as with the primary 
endpoint will be used for superiority testing). 
12.4 Baseline and Subject Disposition  
Demographic data and influenza immunization history will be presented in listings and 
summarized by treatment. Continuous variables including age, weight, height, and BMI will be summarized with mean, median, standard deviation, minimum, and maximum. Count and percentage of subjects will be presented for categorical variables such as sex, race, ethnicity, and immunization history.  
The number of subjects in  different study disposition statuses will be summarized by number 
and, when applicable, percentage (based on vaccinated subjects). Subjects’ completion/discontinuation status will be listed (including subject identifier, date of completion/early discontinuation and, for those who discontinued early, the specific reason(s) for discontinuation). 
12.5 Safety Analyses 
The safety endpoints are defined in Section 10.3.2 . 
12.5.1 Analysis of Secondary Endpoints  
The secondary safety  endpoints are defined in Section 10.3.2.1. 
Safety and tolerability endpoints ( immediate complaints, solicited local and systemic reactions, 
and TEAEs, deaths, SAEs , AEs leading to subject withdrawal,  and NOCDs ) will be summarized 
by treatment using descriptive statistics.  
The original terms used in the eCRFs by Investigators to identify AEs will be coded using the 
MedDRA
® dictionary. All eCRF reported AEs with onset post-vaccination will be included in 
the safety analyses.  
Special attention will be given to those subjects who die, who discontinue from the study due to 
an AE, who experience an SAE (e.g.  summaries, listings, and narrative preparation may be 
provided, as appropriate), or who experience an allergic or allergic- like reaction (see 
Section 13.1.3). 
12.5.2 Analysis of Exploratory Endpoint  
The exploratory safety endpoint  is defined in Section 10.3.2.2. 
The occurrences of medical visits, hospitalizations, and workdays missed (if applicable) will be 
summarized by treatment using descriptive statistics.  
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 64 of 90 12.6 Immunogenicity Analyses 
Unless otherwise mentioned, point estimates and 95% CI will be calculated for all 
immunogenicity endpoints and responses in the Quadrivalent VLP Influenza Vaccine recipients will be compared with the active comparator group using descriptive statistics.   
12.6.1 Analysis of Secondary Endpoints  
The secondary immunogenicity endpoints are defined in Section 10.4.2.1.  
The following analyses for the HI assay (homologous strains) will be performed on the 
immunogenicity PP: 
• GMT (Day 21): The point estimates and the corresponding two sided 95 % CI by treatment 
group and strain will be calculated as the antilog of the mean and 95 % CI of log 
transformed titer values;  
• SC rate (Day 0 and Day 21): The point estimates and the corresponding two- sided 95 % CI 
for subjects achieving SC by treatment group and strain will be calculated to determine 
whether the lower bound of the CI will meet or exceed 3 0 %; 
• SP rate (Day 21): The point estimates and the corresponding two-sided 95 % CI for 
subjects achievin g SP by treatment group and strain will be calculated to determine whether 
the lower bound of the CI will meet or exceed 6 0 %. 
The analyses for the MN and SRH assays (homologous strains) will be performed on the immunogenicity PP. The GMT, GMFR, and SC rate of the MN antibody assay and the GMA, 
GMFR, SC rate, and SP rate  for the SRH antibody assay will be compared between the treatment 
groups using descriptive statistics and 95 % CI. For SC rate and SP rate , Fisher’s exact tests or 
chi square tests will be used. GMT and GMFR for MN and GMA and GMFR for SRH will be 
compared using appropriate analysis of variance models. 
12.6.2 Analysis of Exploratory Endpoint 
The exploratory immunogenicity endpoint is  defined in Section 10.4.2.2. 
The CMI response  will be compared between the treatment groups using appropriate non-
parametric (Wilcox on) models. Additional details will be provided in the SAP. 
13 ADVERSE EVENT REPORTING  
Timely, accurate, and complete reporting and analysis of safety information from clinical studies are crucial for the protection of subjects, Investigators, and the Sponsor, and are mandated by regulatory agencies worldwide. 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 65 of 90 13.1 Definitions  
13.1.1 Serious Adverse Events  
An SAE is any untoward medical occurrence (whether or not considered to be related to the 
study vaccine) that, at any dose:  
• Results in d eath; 
• Is life-threatening (at the time of the event) ; 
Note: the term “life -threatening” in the definition of an SAE refers to an event that put the 
subject at risk of death at the time of the event; it does not refer to an event that hypothetically 
might have caused death if it were more severe;  
• Requires inpatient hospitalization ( ≥ 24 hours) or prolongation of existing hospitalization 
(elective hospitalizations/procedures for pre-existing conditions that have not worsened are excluded) ; 
• Results in persistent or significant disability/incapacity;  
• Is a congenital abnormality/birth defect;  
• Is another medically important event. 
Medical and scientific judgment should be exercised in deciding whether expedited reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalization but that may jeopardize the subject’s health  
or may require an intervention to prevent one of the other outcomes listed in the definition 
above. These events should be considered serious. Examples of such events are intensive 
treatment in an emergency r oom for allergic bronchospasm, blood dyscrasias, or convulsions that 
do not result in hospitalization  or the development of drug dependency or drug abuse. See 
Section 13.1.6 for initial SAE reporting by the Investigator.  
13.1.2 Adverse Events  
An AE or adverse experience is defined as any untoward medical occurrence in a subject or clinical investigation subject who was administered a pharmaceutical product,  with or without a 
causal relationship with the treatment. An AE can be any favorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to a medicinal product.  
Information such as the date and time of onset and resolution (duration), intensity (defined below), serious ness, any required treatment or action taken, outcome, causal relationship to the 
investigational vaccine, and whether the AE caused withdrawal from the study will be collected . 
The intensity of all AEs will be graded as mild (1), moderate (2) severe (3), or potentially life threatening (4), according to the FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (FDA, 2007) for 
the events covered in the guidance and the following definitions for all other events: 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 66 of 90 Mild (Grade 1) : The AE is easily tolerated and does not interfere with usual 
activity; 
Moderate (Grade 2) : The AE interferes with daily activity, but the subject is still able 
to function; 
Severe (Grade 3) : The AE is incapacitating and the subject is unable to work or 
complete usual activity;  
Potentially l ife-threatening 
(Grade 4) : The AE is likely  to be life-threatening if not treated in a timely 
manner. 
The Investigator will be instructed to closely monitor each subject who experiences an AE 
(whether ascribed to the investigational product or not) until the outcome of the AE has been 
determined.  
If any of the solicited local or systemic reactions persist beyond Day 7, these will also be 
recorded as AEs. In this case, the AE start will be set as eight days post-vaccination. The subject 
will be requested to note when the AE resolves and to report this information to the Investigator or clinic staff at the next visit at the clinical site or contact.  
The clinical importance of AEs will be determined based upon the Investigator’s judgment. The Investigator must ensure that any sample obtained to follow up on an AE is properly labeled and stored. The Investigator and others responsible for care of the subjects should institute any supplementary investigations of significant AEs based on the clinical assessment of the likely causative factor. This may incl ude seeking the opinion of a specialist in the field of the AE. 
All AEs occurring within 21 days after vaccination must be reported in the “Adverse Event” 
screen in the subject’s eCRF, irrespective of intensity or whether or not they are considered to be vaccination -related. Thereafter, from Day 22 through to the end of the surveillance period, SAEs, 
AEs leading to withdrawal, and NOCDs (see Section 13.1.4 for definition) will be monitored and 
reported in the eCRF. Additional details on eCRF entries can be found in the eCRF completion guidelines. 
The SAEs and NOCDs will be followed up until complete resolution or stabilization. Follow-up 
of unresolved SAEs, AEs leading to withdrawal, or NOCDs after the end of the surveillance 
period will continue under the discretion of the Investigator. 
13.1.3 Adverse Events of Special Interest  
In the five studies conducted to date, all reported events were monitored for a possible 
hypersensitivity component (events were searched using both narrow and broad standardized 
MedDRA
® queries). Based on these data, there is no evidence of anaphylactic reactions 
associated with use of the Quadrivalent VLP Influenza Vaccine in humans: a small number of 
subjects had potential hypersensitivity reactions judged to be related to vaccine administration (no more than 0.3 % of subjects in any given VLP treatment group experienced one of these events) and the events were distributed fairly evenly among treatment groups, including the placebo and the active comparator groups. However, since severe reactions are considered to be an important potential risk (based on the theoretical risk that using plants for the production of 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 67 of 90 biotherapeutics may induce hypersensitivity) the sponsor will continue to require that appropriate 
medical treatment and supervision are available to manage any possible anaphylactic reactions.  
To collect additional data on these events, Medicago will closely monitor and assess allergic or allergic-like reactions as AEs of special interest. Thus , to collect specific data under this 
protocol, the Investigator should, whenever possible, take a picture of any occurrence of allergic 
or allergic -like reactions and send the anonymized ima ges to Medicago as described in the study-
specific documentation . 
13.1.4 New Onset of Chronic Disease  
In the context of this study, all NOCDs that may plausibly have an allergic, autoimmune or 
inflammatory component are to be reported. Plausibility should be interpreted broadly however; the only clear exceptions are degenerative conditions such as osteoarthritis, age- related 
physiologic ch anges (e.g.  benign prostatic hypertrophy) and life- style diseases (e.g. alcohol -
associated cirrhosis, bronchitis in a smoker, etc.). In this context, most cancers, cardiac conditions, and kidney diseases should be reported. 
NOCDs will be collected from vac cination on Day 0 to the end of the surveillance period and 
reported as an AE or SAE, as applicable.  
13.1.5 Expectedness of an Adverse Drug Reaction  
An “unexpected” adverse reaction is one in which the nature or severity of the event is not 
consistent with information in the current version of the IB. Expedited reporting to the regulatory 
authorities is required if an SAE occurs that is both unexpected and considered possibly, probably, or definitely related to the study vaccine. 
13.1.6 Initial SAE Reporting by the Inves tigator 
Details on safety reporting are defined in the safety management plan (SMP), including SAE 
processing, country-specific reporting requirements, regulatory unblinding, roles and responsibilities of different stake holders, and contact details of personnel responsible for safety reporting.  A brief summary of salient information is presented below.  
SAEs related to pre -treatment study procedures will be reported from the time the ICF is signed. 
All post-vaccination SAEs (treatment -emergent SAEs) will be  reported from the time of 
receiving the study vaccine on Day 0 through to the end of the surveillance period (final scheduled phone contact). The Investigator (or designee) must report, by phone or e- mail, all 
SAEs, whether considered related to the study vaccine or not to Medicago (or its designee)  
within 24 hours of the Investigator learning of the event. The Investigator must also complete, 
sign, and date the paper SAE report form, and send, via e- mail, a copy to the Medicago  safety e-
mail address  and the appropriate regional  e-mail address  within 24 hours of awareness of event: 
Medicago Safety e -mail address:  Medicago -Safety@medicago.com  
  
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 68 of 90 Sponsor Safety Contact:  
 
 
 
Serious AE s will be reported to the local (or contract) IRB by the Investigator according to the 
IRB’s policy and procedures. 
13.1.7 Follow- up Reporting by the Investigator  
All SAEs, regardless of causality, will be followed as described in Section 13.1.2. When 
appropriate, documentation of any medical tests or examinat ions performed will be provided to 
document resolution/stabilization of the event. 13.1.8 Reporting of SAEs Occurring after Surveillance Period or Study Termination 
All SAEs occurring during the safety follow up period will be followed until the end of the 
surveillance period . 
A post-study AE/SAE is defined as any event that occurs outside of the AE/SAE detection period (post surveillance period). Active follow-up for AEs or SAEs will continue until the end of the surveillance period for all subjects. However, aft er the end of the surveillance period, if 
the Investigator learns of any SAE, including death, at any time after a subject has been discharged from the study, and he/she considers the event to be reasonably related to the 
investigational product, the Investigator will promptly notify the Sponsor Safety Contacts for 
Reporting SAEs. 
13.1.9 Causal Relationship 
The Investigator must make the determination of relationship to the study vaccine for each AE.  
The Investigator should decide whether, in his/her medical judgment, there is a reasonable 
possibility that the event may have been caused by the investigational vaccine. If there is any valid reason, even if undetermined or untested, for suspecting a possible cause- and-effect 
relationship between the investigatio nal vaccine and the occurrence of the AE, then the AE 
should be considered “definitely related”, “probably related”, or “possibly related”. Otherwise, if no valid reason exists for suggesting a possible relationship, then the AE should be classified as “probably not related” or “definitely not related”. The following guidance should be followed: 
Definitely Not 
Related: The AE is clearly not related to the administration of the study vaccine. 
Another cause of the event is most plausible; and/or a clinically 
plausible temporal sequence is inconsistent with the onset of the event and the study vaccine administration; and/or a causal relationship is considered biologically implausible. 
Probably Not 
Related: There is no medical evidence to suggest that the AE is  related to the 
study vaccine. The event can be readily explained by the subject’s underlying medical condition or concomitant therapy or lacks a plausible temporal relationship to the study vaccine.  
PPD
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 69 of 90 Possibly Related:  A direct cause and effect relationshi p between the study vaccine and the 
AE has not been demonstrated but there is a reasonable possibility that 
the event was caused by the study vaccine.  
Probably Related:  There probably is a direct cause and effect relationship between the AE 
and the study vaccine. A plausible biologic mechanism and temporal relationship exist and there is no more likely explanation. 
Definitely Related:  There is a direct cause and effect relationship between the AE and the 
study vaccine. Reactions at the injection site (red ness, swelling, and 
pain) will automatically be entered as definitely related to the study vaccine. 
AE outcomes will be classified as recovered/resolved, not recovered /not resolved, 
recovered/resolved with sequelae, recovering/resolving , or death. 
13.1.10Reporti ng of SAEs to Health Authorities and IRB  
Medicago or its designee will be responsible for reporting SAEs that are deemed both possibly 
related to the study vaccine and considered to be unexpected (‘unexpected’ refers to events that 
do not appear in the package labeling or in the study vaccine IB) to the regulatory authorities in an expedited manner.  
The Investigator will be responsible for reporting the SAEs that meet IRB reporting requirements 
directly to the relevant ethical review board as soon as possib le, and will also provide the ethical 
review board with any safety reports prepared by Medicago or its designee. 
All SAEs that are suspected, unexpected serious adverse reactions (SUSARs) should be reported 
to regulatory authorities by facsimile or electro nic transmission as soon as possible but, in no 
event, later than seven calendar days for deaths and life -threatening events, and 15 calendar days 
for other SAEs after Medicago's (or its designee’s) initial receipt of the information . These 
events should be followed to resolution, stabilization, or return to baseline, regardless of conclusion of the study. 
14 INVESTIGATIONAL PRODUCT INFORMATION 
14.1 Identity of Investigational Product 
The study vaccine is a Quadrivalent VLP Influenza Vaccine composed of recombinant  H1, H3, 
and two B proteins (hemagglutinin) expressed as VLPs . 
14.1.1 Study Vaccine Composition 
The Quadrivalent VLP Influenza Vaccine consists of a mix of VLPs from four strains , each 
bearing the hemagglutinin of one of the recommended virus strains (2018-2019 influenza 
season), in a phosphate buffered saline (PBS) solution  (100 mM NaKPO
4, 150 mM 
NaCl) and 0.01 % polysorbate 80 at pH 7.4). The Quadrivalent VLP Influenza Vaccine will be 
supplied in type 1 glass  pre-filled syringes . 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 70 of 90 14.2 Active Comparator 
The active comparator will be  either Fluarix® (produced by GlaxoSmithKline and marketed as 
Fluarix® Tetra or Fluarix® Quadrivalent in different regions) and/or FluLaval® (produced by ID 
Biomedical of Quebec and distributed by GlaxoSmithKline Inc as either FluLaval® T etra or 
FluLaval® Quadrivalent in different regions). The se quadrivalent influenza vaccines contains 
four split-virion, inactivated influenza virus strains propagated in embryonated chicken eggs, based on the influenza strains recommended by WHO for the 2018-2019 influenza season . Each 
0.5 mL dose of vaccine contains 15 µg of hemagglutinin of each of the four influenza virus strains. 
14.3 Preparation and Administration of Study Vaccine  
The study treatment  (including both the VLP vaccine and the active comparator ) will be prepared 
by unblinded staff members at the clinical site as described in the Investigational Product Management Manual. The prepared study treatment will subsequently be administered to 
subjects by an unblinded staff member.  
Note: The personnel responsible for treatment  preparation can also perform the vaccination (if 
certified and qualified to do it) as this person would already be unblinded. The unblinded staff members must not be involved in the evaluation of any AEs or reactogenicity evaluations following vaccination. 
The products to be used for study treatment  administration will be handled in a clean 
environment in an aseptic manner for preparation for injection as follows: 
• For the administration of the 30 μg /strain vaccine dose, the site will use a pre-filled syringe ; 
• For the administration of the 15 μg/strain active  comparator, 0.5 mL (15  µg/strain), the site  
will prepare and administer  the vaccine as per the manufacturer’s information . 
All study treatments  will be administered as an IM injection of 0.5 mL. The needle to be used for 
the injection should be of sufficient length to reach the substance of the muscle. According to randomization scheme, subjects will receive either the Quadrivalent VLP Influenza Vaccine 
(30 μg/strain ) or the active comparator  in the deltoid muscle of (preferably) the non-dominant 
arm. Whenever possible, the injection will be given in the opposite arm from which blood samples are drawn, when applicable. 
The product administered will be recorded in the Investigational Product Accountability Records 
form (refer to Investigational Product Management Manual) by the clinical site, which will be 
separate from the study medication record for drug preparation. After drug accountability 
monitoring and reconciliation has been completed  by the site and unblinded monitor , all study 
treatment s (unused syringes  and used and unused vials) will be destroyed locally upon 
Medicago’s approval or returned  to Medicago (or its designee) in accordance with instructions 
provided in the Investigational Product Management Manual.  
Further specific information relating to treatment  preparation, storage, and shipment is provided 
in the Investigational Product Management Manual. 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 71 of 90 14.4 Preparation, Handling, Storage, and Precautions for Use 
The study treatment  should be stored in an access- restricted area between 2 ºC and 8 ºC and 
protected from light ; the vaccine should, however, be at room temperature before administration 
(i.e. the vaccine should not be administered cold and should be taken out of the refrigerator at 
least five minutes prior to administration ). In the event of a storage temperature deviation outside 
of the permitted window of 2 ºC to 8 ºC, the study treatment  should be quarantined (at the 
required storage temperature) and M edicago (or its designee) contacted immediately.  
Note: The vaccine must NEVER be frozen, since freezing destroys activity; any vaccine that 
has been frozen must not be used. 
Note: The vaccine must NEVER be shaken or vortexed. 
Note: The treatments  must NOT be administered intravenously, subcutaneously, or 
intradermally.  
The Investigational Product Management Manual provides additional details on treatment  
preparation, handling and storage.  
14.5 Packaging 
The Quadrivalent VLP Influenza Vaccine will be packaged in boxes containing pre -filled 
syringes of the same treatment.  The active comparator  will be provided as packaged by the 
manufacturer . 
14.6 Labeling  
The pre-filled syringes  and the vials will have a product and study- specific label containing 
information that meets the applicable regulatory requirements. The study dispensing labels will include study identifier, name of treatment ( or code), directions for use, route of administration, 
storage conditions, and a period of use. 
Blinding measures will be applied to maintain the observer-blindness of the blinded staff and to 
allow identification of the study treatment only by staff involved in the 
preparation/administration of the study vaccine/active comparator . 
14.7 Drug Accountability  
The Investigator is responsible for ensuring that all study treatments received at the site are 
inventoried and accounted for throughout the study. The dispensing of study treatment to each subject must be documented on the Investigational Product Accountability Records form.  
The study treatments or drugs must be handled in strict accordance with the Investigational 
Product Management Manual and the syringe and vial label and will be stored in a limited access 
area or in a locked cabinet under appropriate environmental conditions. All u nused study drugs 
must be available for verification by Medicago’s (or its designee’s) unblinded site monitor 
during on- site monitoring visits. The return of all unused study drugs to Medicago  (or its 
designee) for destruction will be documented on the Drug Return Form. When the site is 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 72 of 90 authorized by Medicago (or its designee) to destroy study drug supplies on site, this must also be 
documented. 
The study drug should be dispensed under the supervision of the Investigator ( or a qualified 
member of the investigational staff ), who remains blinded as to which treatment is administered . 
The study drug will be supplied only to subje cts participating in the study. Returned study drugs 
may not be relabeled or reassigned for use for other subjects. The Investigator agrees neither to 
dispense the study drug from, nor to store  it at, any site other than the study centers agreed upon 
with Medicago  (or its designee). 
15 STUDY- SPECIFIC MATERIALS  
The Inves tigator will be provided with the following: 
• eCRF; 
• Source documents (when applicable) ; 
• Forms and questionnaires for special assessments; 
• Thermometers and measurements template; 
• Study manuals. 
16 ETHICAL ASPECTS  
16.1 Study -Specific Design Considerations  
On-going medical review will be performed by Medicago (or its designee)  throughout the 
duration of the study; s ubjects will be given any new information that may affect their decision 
to continue participation in the study. Since the use of a placebo would raise ethical concerns for individuals of this age group (65 
years of age and older), who are considered at risk of complications from seasonal influenza, the control selected for this study is an active comparator. 
Blood samples will be collected from a subset of subjects for immunogenicity analysis, although not all may  be analysed  (sample analyses may be restricted to those subjects who present with 
influenza during the surveillance period). Since b lood sample collection is a minimally invasive 
procedure and the amount of blood collected will be a relatively small amount ( Table 5), the 
benefits of obtaining this data outweigh the small level of risk associated with the collection of samples that may not require analysis.  
16.2 Regulatory Ethics Compliance 
16.2.1 Investigator Responsibilities  
The Investigator is responsible for ensuring that the study is performed in accordance with the protocol, current International Conference on Harmonisation ( ICH) guidelines on Good C linical 
Practice (GCP), and applicable regulatory and country- specific req uirements.  
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 73 of 90 GCP is an international ethical and scientific quality standard for designing, conducting, 
recording, and reporting studies that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety, a nd well-being of study 
subjects are protected, consistent with the principles that originated in the Declaration of Helsinki, and that the study data are reliable . 
16.2.2 Independent Ethics Committee or Institutional Review Board 
Before the start of the study, th e Investigator (or Medicago, where required) will provide the 
independent e thics committee (IEC)/IRB with current and complete copies of the following 
documents (as required by local regulations): 
• Final protocol and, if applicable, amendments to the protocol; 
• Sponsor-approved ICF (and any other written materials to be provided to the subjects); 
• IB (or equivalent information) and amendments/addenda; 
• Sponsor-approved subject recruiting materials;  
• Information on compensation for study-related injuries or payments to subjects for participation in the study, if applicable;  
• Investigator’s curriculum vitae  or equivalent information (unless not required, as 
documented by the IEC/IRB); 
• Information regarding funding, name of the sponsor, institutional affiliations, ot her 
potential conflicts of interest, and incentives for subjects; 
• Any other documents that the IEC/IRB requests to fulfill its obligation.  
This study will be undertaken only after the IEC/IRB has given full approval of the final protocol, amendments (if any, excluding the ones that are purely administrative in nature, with no consequences for subjects, data, or study conduct), the ICF, applicable recruiting materials, and subject compensation programs, and Medicago (or its designee) has received a copy of t his 
approval. This approval letter must be dated and must clearly identify the IEC/IRB and the documents being approved. In addition, the Investigator must wait for written confirmation from 
Medicago  (or its designee) that the study can be started.  
During the study , the Investigator (or Medicago [or its designee], where required) will send the 
following documents and updates to the IEC/IRB for their review and approval, where 
appropriate: 
• Protocol amendments; 
• Revision(s) to ICF and any other written materials to be provided to subjects; 
• If applicable, new or revised subject recruiting materials approved by Medicago; 
• Revisions to compensation for study-related injuries or payment to subjects for participation in the study, if applicable;  
• New edition(s) of the IB and amendments/addenda; 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 74 of 90 • Summaries of the study at intervals stipulated in guidelines of the IEC/IRB (at a minimum,  
annually); 
• Reports of AEs that are serious, unlisted/unexpected, and associated with the study drug 
(when applicable); 
• New information th at may adversely affect the safety of the subjects or the conduct of the 
study; 
• Deviations from or changes to the protocol to eliminate immediate hazards to subjects; 
• Reports of deaths of subjects under the Investigator’s care; 
• Notification if a new Investigator is responsible for the study at any of the sites; 
• Development Safety Update Report and Line Listings, where applicable;  
• Any other requirements of the IEC/IRB. 
At least once a year, the IEC/IRB will be asked to review and reapprove this study. The reapproval should be documented in writing. At the end of the study, the Investigator (or Medicago  [or its designee], where required) will notify the IEC/IRB of study completion. 
16.2.3 Informed Consent  
Each subject who participates in the study must first give written consent according to local 
requirements after the nature of the study has been fully explained, including the risks and requirements of the study. The consent form must be signed before performing any study- related 
activity. The consent form that is used must have been  approved by regulatory authorities, 
Medicago , and the reviewing IEC/IRB. The informed consent should be in accordance with 
principles that originated in the Declaration of Helsinki, current ICH and GCP guidelines, applicable regu latory requirements, and Medicago policy. During the study, s ubjects will be 
given any new information that may affect their decision to continue their participation  in the 
study. They will be told that their consent to participate is voluntary and that it may be withdrawn at any time, with no reason given, and without penalty or loss of benefits to which they would otherwise be entitled. Only subjects who are fully able to understand the risks, 
benefits, and potential AEs of the study and who provide their consent voluntarily will be 
enrolled. 
16.2.4 Privacy of Personal Data 
The collection and processing of personal data from subjects enrolled in this study will be 
limited to those data that are necessary to support the development, registration, and future marketing of the investigational product. The data must be collected and processed with adequate 
precautions to ensure confidentiality and compliance with applicable data privacy protection laws and regulations. Appropriate technical and organizational measures to protect the personal data against unauthorized disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be in place. Medicago (or its designee) personnel whose responsibilities 
require access to personal data agre e to keep the identity of study subjects confidential. 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 75 of 90 17 ADMINISTRATIVE REQUIREMENTS  
17.1 Protocol Amendments  
Neither the Investigator nor Medicago will modify this protocol without a formal amendment. 
All protocol amendments must be issued and approved by Medica go, and signed and dated by 
the Investigator. Protocol amendments must not be implemented without prior IEC/IRB approval or when the relevant competent authority has raised any grounds for non- acceptance, except 
when necessary  in order to eliminate an imme diate hazard  to the subjects, in which case the 
amendment must be promptly submitted to the IEC/IRB and relevant competent authority. Documentation of amendment approval by the Investigator and IEC/IRB must be provided to Medicago or its designee. 
Note that administrative changes may be implemented without prior IRB approval; however, the Investigator or Medicago, as applicable, must notify the IRB of any administrative change and ensure that the IRB acknowledges receipt of the administrative changes.  
The Investigator is responsible for notifying the IRB of all protocol amendments and ensuring 
that the IRB has approved any amendments when local IRBs are used. When a central IRB is used, Medicago or its designee will inform the IRB on behalf of the sites.  
During the course of the study, in situations where a departure from the protocol is unavoidable, 
the Investigator or other physician in attendance will contact the appropriate Medicago representative or its designee (see Contact Information pages provided se parately). Except in 
emergency situations, this contact should be made before implementing any departure from the protocol. In all cases, contact with Medicago or its designee must be made as soon as possible to 
discuss the situation and to agree on an appropriate course of action. The data recorded in the 
eCRF and source documents will reflect any departure from the protocol, and the source documents will describe this departure and the circumstances that made a deviation necessary . 
17.2 Regulatory Documentation  
17.2.1 Regulatory Approval/Notification 
This protocol and any amendment(s) must be submitted to the appropriate regulatory authorities in each respective country, as applicable. A study may not be initiated until all local regulatory requirements  are met. 
17.3 Source Documentation  
At a minimum, source documentation must be available for the following information: 
• Subject identification, eligibility, and study identification; 
• ICF discussion and date of informed consent; 
• Dates of visits; 
• Results of safet y and study procedures as required by the protocol; 
• Record of all reactions, AEs , respiratory illnesses, ILIs, and associated follow ups; 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 76 of 90 • Concomitant medication; 
• Drug receipt, dispensing, and return records; 
• Study drug administration information; 
• Date of study completion  and reason for early discontinuation of study drug or withdrawal 
from the study, if applicable. 
It is recommended that the author of an entry in the source documents be identifiable. 
At a minimum, the type and level of detail of source data available for a study subject should be 
consistent with that commonly recorded at the site as a basis for standard medical care. If 
Investigator judgement was used in the determination of eligibilit y, an explanation for inclusion 
of the subject in the study must be provided in the source documents. Specific details required as source data for the study will be reviewed with the Investigator before the study and will be 
described in the monitoring guidelines (or other equivalent document). 
17.3.1 Diary and Memory  Aid 
Subjects will be provided with a diary in which to record reactions and other safety information. 
Subject diaries are considered source documents ; the diary  will be returned by the subject to  the 
site after Day 21 (the method of return will be defined in the study- specific documentation ) and 
kept with each subject’s study chart. In the event the diary  is lost by the subject, information 
collected by the coordinator or designee and information reca lled by the subject will serve as the 
source data for this subject. The recalled information will be captured in the source documents. 
Corrections to data entered by the subject in the diary  should only be performed by the subject 
him/herself, when possibl e. Clarifications can be made in the comment section of the diary  by 
the study personnel if the subject is not present onsite to make the correction him/herself. Subjects will be provided with a memory aid to record  information on respiratory illnesses and 
ILIs, and to record information on SAEs, NOCDs, AEs leading to withdrawal, and reportable 
concomitant medications from the Day 21 visit to the end of the study. These memory  aids will 
not be collected by the site and are intended to be used by the subject to help them in reporting 
this information to site staff.  
17.4 Case Report Form Completion  
An eCRF  will be provided for each subject who is randomized and receives a dose of study drug. 
Screening failures will also be entered in an  eCRF; data entered should include date of b irth and 
reason for screening failure. 
Data must be entered into the eCRFs in English. The Investigator must verify that all data entries 
in the eCRFs are accurate and correct. All eCRF entries, corrections, and alterations must be 
made by the Investigator or other authorized study-site personnel. 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 77 of 90 17.5 Quality Control (Study Monitoring) 
In accordance with applicable regulations, GCP, and Medicago  (or its designee) procedures, the 
site will be contacted prior to the study s tart to review the protocol and study requirements with 
the clinical study staff. Medicago (or its designee) will review their responsibilities to satisfy 
regulatory, ethical , and company (Medicago)  requirements.  
The Investigator or institution, if applicable, will authorize and provide direct access to  all 
relevant documents to allow review of the appropriate conduct of the study by Medicago’s (or its 
designee’s) monitor. The Investigator(s) must allocate their time and the time of their staff to the 
monitors, discuss any findings or issues, and take appropriate actions to maintain the quality and 
integrity of the study data and conduct. 
Protocol deviations will be reviewed by Medicago (or its designee) to identify any non-
compliances likely to have a significant effect on the safety and rights of a subject or the reliability and robustness of the data generated. These deviations will be included in the clinical 
study report . 
17.6 Quality Assurance 
To ensure compliance with GCP and all other applicable regulatory requirements, Medicago (or its designee) may conduct quality assurance assessments and/or an audit of the site. Regulatory 
agencies may conduct regulatory inspections at any time during or after completion of the study. If an audit or an inspection is conducted, the Investigator and/or institution (if applicable) must agree to grant auditors or inspectors direct access to all relevant documents and to allocate their time and the time of their  staff to d iscuss the conduct of the study and any findings or issues, and 
to implement corrective and/or preventative actions to address any findings or issues identified. 
17.7 Record Retention  
Following closure of the study, the Investigator must maintain all site study records in a safe and 
secure location. The records must be easily accessible when needed (e.g. for a Medicago  [or its 
designee]  audit or regulatory inspection) and must be available for review in conjunction with 
assessment of the facility, sup porting systems, and relevant site staff.  
When permitted by local laws and regulations or institutional policy, some or all of the records may be maintained in a format other than a hard copy (e.g. scanned electronic). The Investigator 
must ensure that all reproductions are legible and are a true and  accurate copy of the original.  
The Investigator must follow the time period for retaining the site records in order to comply with all applicable regulatory requirements. The minimum retention time will meet the strictest 
standard applicable to a particular site, as dictated by local laws and regulations, Medicago (or its 
designee) standard operating procedures (SOPs), and/or institutional requirements . The 
Investigator must contact Medicago (or its designee) prior to the disposal of any study 
documents at the end of the retention period. 
If the responsible Investigator retires, relocates, or, for any other reason, withdraws from the 
responsibility of keeping the study records, custody must be transferred to anot her person who 
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 78 of 90 will accept the responsibility. Medicago (or its designee) must be notified in writing of the name 
and address of the new custodian. Under no circumstance shall the Investigator relocate or 
dispose of any study documents without having obtained prior written approval from Medicago (or its designee) . 
If it becomes necessary for Medicago or the appropriate regulatory authority to review any documentation relating to this study, the Investigator must permit access to such reports. 
17.8 Study Completion/ Termination  
17.8.1 Study Completion 
The study will be  considered to be completed with the last contact with  the last subject 
participating in the study. The final data from the investigational site will be sent to Medicago 
(or designee) after completio n of the final subject visit at that site. Investigational sites will be 
closed after study completion. An investigational site is considered closed when all required 
documents and study supplies have been collected, all data have been entered , monitored, 
locked, and signed and a site closure visit has been performed.  
17.8.2 Study Termination 
Medicago (or its designee) reserves the right to close the investigational site or terminate the 
study at any time for any reason at the sole discretion of Medicago. Investigational sites will be 
closed aft er study termination  once Medicago (or its designee) has completed all study related  
tasks. Reasons for the early closure of an investigational site by Medicago (or its designee) or the 
Investigator may include, but are not limited to: 
• Failure of the Investigato r to comply with the protocol, Medicago’s (or its designee’s) 
procedures, or GCP guidelines; 
• Inadequate recruitment of subjects by the Investigator; 
• Discontinuation of further drug development. 
The Investigator  may initiate site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended closure. 
Site closure following an Investigator request can only be performed when all active study 
subjects have completed  the study period, Medicago (or its designee) has collected all required 
documents and study supplies, and all data have been entered, monitored and locked. 
17.9 Registration of Clinical Studies and Disclosure of Results  
Study information from this study will be posted on publicly available clinical trial registries in 
countries where applicable and will inclu de information required by law. In addition, the results 
summary will be posted to the same clinical trial registr ies, to the extent specified by law,  and 
will include information required by regulatory authorities.  
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 79 of 90 18 REFERENCES  
CDC. Seasonal Influenza (Flu) : What You Should Know and Do this Flu Season If You Are 65 
Years and Older ; cited 12 February 2018.. Available  from 
https://www.cdc.gov/flu/about/disease/65over.htm 
DiazGranados C, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in 
children and non- elderly adults: a systematic review with meta -analyses of controlled 
trials. Vaccine. 2012;31(1):49-57.  
FDA. Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent 
Volunteers Enrolled in Preventive Vaccine Clinical Trials . 2007. 
Jefferson T, Rivetti D , Rivetti A, Rudin W, DiPietrantonj C, Demicheli  V. Efficacy and 
effectiveness of influenza vaccines in elderly people: a systematic review. The Lancet . 
2005;366(9492):1165-1174. 
McElhaney JE. Influenza Vaccine Responses in Older Adults. Ageing Res Rev . 2011;10(3):379-
388. 
Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley  PM, Weintraub E, 
Bridges CB. The annual impact of seasonal influenza in the US: measuring disease 
burden and costs. Vaccine. 2007;25(27):5086-5096.  
Osterholm M, Kelley N, Sommer A, Belongia E. Efficacy and effectiveness of influenza 
vaccines: a systematic review and meta- analysis. The Lancet Infectious Diseases . 
2012;12(1):36-44.  
Palache A. Seasonal influenza vaccine provision in 157 countries (2004-2009) and the potential 
influence of national public health policies. Vaccine. 2011;29(51 ):9459-9466.  
Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson JA, Winter AL, Drews SJ, 
Fonseca K, Charest H, Gubbay JB, Petric M, Krajden M, Kwindt TL, Martineau C, Eshaghi A, Bastien N, Li Y. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network. 2015;20(4):21022. 
Zost SJ, Parkhouse K, Gumina ME , Kim K, Perez SD, Wilson PC, Treanor JJ , Sant AJ, Cobey S, 
Hensley SE. Contemporary H3N2 influenza viruses have a glycosylati on site that alters 
binding of antibodies elicited by egg- adapted vaccine strains . PNAS. 
2017;114(47):12578-12583. 
  
Clinical Pr otocol Version 1.2  CP-PRO-QVLP-014 
Plant-derived Quadrivalent VLP Influenza Vaccine  
 
 
 Confidential Information  
Medicago R&D Inc. Page 80 of 90 19 APPENDICES  
The clinical documents included in the appendices are meant as examples only; the actual 
documents used during the trial may dif fer slightly.  
19.1 Appendix 1 – Sample Ruler to Measure Local Reactions  
 
  
